Document:

Exhibit 10.14

 Exhibit 10.14 
  
 Certain confidential information contained in this document, marked by brackets and asterisks, [*], has been omitted pursuant to a
request for confidential treatment pursuant to Rule 24b–2 of the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission. 
  
 ROW TERRITORY LICENSE AGREEMENT 
  
 BY AND AMONG 
  
 SHIRE PHARMACEUTICALS IRELAND LIMITED 
  
 SHIRE PHARMACEUTICALS GROUP PLC 
  
 AND 
  
 NEW RIVER PHARMACEUTICALS INC. 
  
 DATED AS OF MARCH 31, 2005 

  
 TABLE OF CONTENTS

  

					
	 	  	 	  	Page

	 ARTICLE 1
	  	 DEFINITIONS
	  	2
			
	 ARTICLE 2
	  	 MANAGEMENT OF COLLABORATION
	  	11
			
	 2.1
	  	 General
	  	11
			
	 2.2
	  	 Joint Development Committee (JDC)
	  	11
			
	 2.3
	  	 Joint Supply Committee (JSC)
	  	13
			
	 2.4
	  	 Joint Intellectual Property Committee (JIPC)
	  	14
			
	 2.5
	  	 General Committee Membership and Procedures
	  	14
			
	 2.6
	  	 Committee Decision-Making
	  	16
			
	 ARTICLE 3
	  	 DEVELOPMENT AND REGULATORY RESPONSIBILITIES
	  	17
			
	 3.1
	  	 Overview
	  	17
			
	 3.2
	  	 Development Plans
	  	17
			
	 3.3
	  	 Regulatory Activities
	  	18
			
	 3.4
	  	 Development in the ROW Territory for ADHD and Other Indications
	  	18
			
	 3.5
	  	 Shared Expenses
	  	20
			
	 3.6
	  	 Use of Third Parties
	  	21
			
	 3.7
	  	 Assistance
	  	21
			
	 3.8
	  	 Compliance with Laws
	  	21
			
	 ARTICLE 4
	  	 COMMERCIALIZATION OF COLLABORATION PRODUCTS
	  	21
			
	 4.1
	  	 Principles of Commercialization
	  	21
			
	 4.2
	  	 Sales and Distribution of Collaboration Products to Third Parties
	  	21
			
	 4.3
	  	 Marketing Plans for ROW Territory
	  	22
			
	 4.4
	  	 Regulatory Obligations During Commercialization
	  	22
			
	 4.5
	  	 Diligence in Commercialization
	  	22
			
	 4.6
	  	 Cost of Commercialization
	  	22
			
	 4.7
	  	 Use of Third Parties
	  	22
			
	 4.8
	  	 Promotional Materials
	  	23
			
	 4.9
	  	 Compliance with Laws
	  	23
			
	 ARTICLE 5
	  	 MANUFACTURE OF COLLABORATION PRODUCTS
	  	23
			
	 5.1
	  	 Manufacture and Supply
	  	23
			
	 5.2
	  	 Specifications and Terms of Supply; Multiple Sources
	  	24

  

 i 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page

	 5.3
	  	 Manufacture by Shire; Commercial Supply by Shire
	  	24
			
	 5.4
	  	 Supply Terms
	  	25
			
	 ARTICLE 6
	  	 FINANCIAL TERMS
	  	25
			
	 6.1
	  	 Licensing Fee
	  	25
			
	 6.2
	  	 Milestone Payment
	  	25
			
	 6.3
	  	 [*]
	  	26
			
	 ARTICLE 7
	  	 PAYMENT TERMS
	  	26
			
	 7.1
	  	 Payment Method
	  	26
			
	 7.2
	  	 Payment Schedules; Reports
	  	27
			
	 7.3
	  	 Currency Conversion
	  	27
			
	 7.4
	  	 Legal Restrictions
	  	27
			
	 7.5
	  	 Taxes
	  	27
			
	 7.6
	  	 Records Retention; Audit
	  	28
			
	 ARTICLE 8
	  	 LICENSES
	  	29
			
	 8.1
	  	 Licenses to Shire
	  	29
			
	 8.2
	  	 Licenses to New River
	  	30
			
	 8.3
	  	 Sublicensing
	  	30
			
	 8.4
	  	 Scope of Licenses
	  	30
			
	 8.5
	  	 No Implied Licenses
	  	30
			
	 8.6
	  	 Exclusivity
	  	30
			
	 8.7
	  	 Nonassertion
	  	30
			
	 8.8
	  	 [*]
	  	30
			
	 ARTICLE 9
	  	 CONFIDENTIALITY
	  	31
			
	 9.1
	  	 Confidential Information
	  	31
			
	 9.2
	  	 Publicity; Filing of this Agreement
	  	33
			
	 9.3
	  	 Publication
	  	33
			
	 9.4
	  	 Use of Names
	  	34
			
	 9.5
	  	 Confidentiality of this Agreement
	  	34
			
	 9.6
	  	 Disclosures Under Existing NDA
	  	34
			
	 9.7
	  	 Survival
	  	34

  

 ii 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page

	 ARTICLE 10
	  	 OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS
	  	34
			
	 10.1
	  	 Ownership
	  	34
			
	 10.2
	  	 Disclosures; Disputes Regarding Inventions
	  	35
			
	 10.3
	  	 Patent Filings
	  	35
			
	 10.4
	  	 Third-Party Patent Rights
	  	37
			
	 10.5
	  	 Enforcement and Defense of Patents
	  	37
			
	 10.6
	  	 Notice of Certification
	  	40
			
	 10.7
	  	 Patent Term Extensions
	  	40
			
	 10.8
	  	 Listing of Patents
	  	40
			
	 10.9
	  	 Trademarks and Copyrights
	  	41
			
	 ARTICLE 11
	  	 REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY
	  	43
			
	 11.1
	  	 Representations, Warranties and Covenants
	  	43
			
	 11.2
	  	 Limitation on Representations or Warranties
	  	48
			
	 11.3
	  	 Performance by Affiliates
	  	48
			
	 11.4
	  	 Disclaimer of Warranty
	  	48
			
	 11.5
	  	 Limitation of Liability
	  	48
			
	 11.6
	  	 Essential Basis
	  	49
			
	 ARTICLE 12
	  	 TERM AND TERMINATION
	  	49
			
	 12.1
	  	 Term
	  	49
			
	 12.2
	  	 Breaches (General)
	  	49
			
	 12.3
	  	 Allegations of Material Breach
	  	49
			
	 12.4
	  	 Other Termination by Shire
	  	51
			
	 12.5
	  	 Other Termination By New River
	  	51
			
	 12.6
	  	 Termination for Government Action
	  	52
			
	 ARTICLE 13
	  	 EFFECTS OF TERMINATION
	  	53
			
	 13.1
	  	 Post-Termination Activities by Shire
	  	53
			
	 13.2
	  	 Post-Termination Activities by New River
	  	55
			
	 13.3
	  	 Accrued Rights
	  	57
			
	 13.4
	  	 Confidential Information
	  	57

  

 iii 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page

	 13.5
	  	 Survival
	  	57
			
	 13.6
	  	 Liability Following Termination
	  	57
			
	 ARTICLE 14
	  	 INDEMNIFICATION; INSURANCE
	  	57
			
	 14.1
	  	 Indemnification
	  	57
			
	 14.2
	  	 Notice of Claim
	  	58
			
	 14.3
	  	 Control of Defense
	  	58
			
	 14.4
	  	 Right to Participate in Defense
	  	58
			
	 14.5
	  	 Settlement
	  	58
			
	 14.6
	  	 Cooperation
	  	59
			
	 14.7
	  	 Expenses of the Indemnified Party
	  	59
			
	 14.8
	  	 Treatment of Certain Losses
	  	59
			
	 14.9
	  	 Insurance
	  	60
			
	 14.10
	  	 Guaranty
	  	60
			
	 ARTICLE 15
	  	 DISPUTE RESOLUTION
	  	60
			
	 15.1
	  	 Disputes
	  	60
			
	 15.2
	  	 Litigation
	  	60
			
	 15.3
	  	 Injunctive Relief
	  	61
			
	 15.4
	  	 Governing Law
	  	61
			
	 ARTICLE 16
	  	 MISCELLANEOUS
	  	61
			
	 16.1
	  	 Entire Agreement; Amendment
	  	61
			
	 16.2
	  	 Force Majeure
	  	61
			
	 16.3
	  	 Notices
	  	62
			
	 16.4
	  	 Independent Contractors
	  	63
			
	 16.5
	  	 Non-Solicitation
	  	63
			
	 16.6
	  	 Maintenance of Records
	  	63
			
	 16.7
	  	 United States Dollars
	  	63
			
	 16.8
	  	 No Strict Construction
	  	63
			
	 16.9
	  	 Assignment
	  	63
			
	 16.10
	  	 Counterparts
	  	64
			
	 16.11
	  	 Further Actions
	  	64
			
	 16.12
	  	 Severability
	  	64
			
	 16.13
	  	 Ambiguities
	  	64
			
	 16.14
	  	 Headings
	  	64
			
	 16.15
	  	 No Waiver
	  	64

  

 iv 

 Exhibits 
  

			
	EXHIBIT A	  	DETERMINATION OF CERTAIN ACCOUNTING TERMS
	EXHIBIT B	  	ADDITIONAL SUPPLY TERMS
	EXHIBIT C	  	JOINT PRESS RELEASE
	EXHIBIT D	  	TECHNICAL TRADE SECRETS
	EXHIBIT E	  	CERTAIN PRODUCTS OF SHIRE

  

 - 1 - 

  
 ROW TERRITORY LICENSE
AGREEMENT 
  
 THIS ROW TERRITORY LICENSE AGREEMENT (the
“Agreement”) is dated as of March 31, 2005 by and among SHIRE PHARMACEUTICALS IRELAND LIMITED, an Irish resident company having a principal place of business at 2nd Floor, Unit 1A, Citylink Business Park, Old Naas Road, Dublin 12,
Ireland (“Shire”), SHIRE PHARMACEUTICALS GROUP PLC, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the
provisions of Section 14.10 of this Agreement, and NEW RIVER PHARMACEUTICALS INC., a Virginia corporation having a principal place of business at 1881 Grove Avenue, Radford, Virginia 24141 (“New River”). Shire and New River are
sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
  
 RECITALS 
  
 WHEREAS, New River is a specialty pharmaceutical company focused on developing novel pharmaceuticals that are safer and improved versions of
widely-prescribed pharmaceutical products, and is clinically developing a proprietary amphetamine conjugate for the treatment of attention deficit/hyperactivity disorder in pediatric and adult patients; 
  
 WHEREAS, Shire is a worldwide, specialty pharmaceutical company
engaged in the development, manufacturing and marketing of pharmaceutical products; and 
  
 WHEREAS, on January 31, 2005 (the “Effective Date”), New River and Shire LLC entered into that certain Collaboration Agreement (the “January Agreement”) that established a
broad collaboration for the further development and commercialization of Compound in both the US Territory and ROW Territory, with the objective of utilizing the areas of expertise of both New River and Shire and its Affiliates to provide products
to patients; 
  
 WHEREAS, pursuant to Section 17.16 of the
January Agreement, New River and Shire LLC agreed to divide the January Agreement into two separate agreements: one relating to the US Territory and the other relating to the ROW Territory; 
  
 WHEREAS, as contemplated by Section 17.16 of the January Agreement,
New River and Shire LLC, an Affiliate of Shire, are entering into that certain US Territory Collaboration Agreement (the “US Agreement”) simultaneously with the execution of this Agreement; and 
  
 WHEREAS, this Agreement, together with the ROW Agreement, supercede
and replace the January Agreement in its entirety. 
  

 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained
herein, the Parties, intending to be legally bound, agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 The following terms shall have the following meanings as used in this Agreement: 
  

1.1 “Act” means the United States Federal Food, Drug and Cosmetics Act, as amended from time to time, and the rules,
regulations and guidelines promulgated thereunder. 
  
 1.2
“ADHD” means attention deficit/hyperactivity disorder in human beings. 
  
 1.3 “Adolescent” means a human being that has attained the age of thirteen (13) but is less than eighteen (18) years of age. 
  
 1.4 “Adult” means a human being that has attained the age of eighteen (18). 
  
 1.5 “Affiliate” means a Person that controls, is
controlled by or is under common control with a Party. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means the
actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person, whether by the ownership of at least fifty percent (50%) of the voting stock of such Person (it being understood
that the direct or indirect ownership of a lesser percentage of such stock shall not necessarily preclude the existence of control), or by contract or otherwise. 
  
 1.6 “Business Day” means any day other than (i) Saturday or Sunday or (ii) any other day on which
banks in New York, New York, United States, Dublin, Ireland or London, England are permitted or required to be closed. 
  
 1.7 “cGCP” means the current Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing,
recording, analyses, and reporting of clinical trials, including the requirements in 21 C.F.R. Parts 11, 50, 54, 56, 312, and 314, that provide assurance that the data and reported results are credible and accurate, and that the rights, integrity,
and confidentiality of trial subjects are protected. 
  
 1.8
“cGLP” means current Good Laboratory Practices (i) as promulgated under the Act at 21 C.F.R. Part 58, as the same may be amended or re-enacted from time to time and (ii) as required by Law in countries other than the United
States where non-clinical laboratory studies are conducted. 
  
 1.9 “cGMP” means all applicable standards relating to manufacturing practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical products, including (i) the
principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 210 and 211 and The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products as each may be
amended from time to time, (ii) the principles detailed in the ICH Q7A guidelines, (iii) if Shire notifies New River that Shire intends to Commercialize a Collaboration Product in a country, Laws promulgated by any Governmental Authority in such
country having jurisdiction over the Manufacture of Compound or Collaboration Product, or (iv) if Shire notifies 

  

 - 2 - 

 
New River that Shire intends to Commercialize a Collaboration Product in a country, guidance documents promulgated by any Governmental Authority in such
country having jurisdiction over the Manufacture of Compound or Collaboration Product (including but not limited to advisory opinions, compliance policy guides and guidelines), which guidance documents are being implemented within the pharmaceutical
manufacturing industry. 
  
 1.10 “Child”
means a human being that has not attained the age of thirteen (13). 
  
 1.11 “Collaboration Product” means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all
Improvements thereto. 
  
 1.12 “Combination
Product” means any Collaboration Product that contains the Compound and one or more pharmaceutically active ingredients in addition to Compound, and any and all Improvements thereto. 
  
 1.13 “Commercialization” means any and all activities
directed to the commercial Manufacturing, marketing, offering for sale and selling of a Collaboration Product, including advertising, educating, planning, marketing, promoting, distributing and conducting market and product support studies and
post-marketing safety surveillance and reporting. 
  
 1.14
“Committee” means the JDC, JSC or JIPC, as the case may be. 
  
 1.15 “Compound” has the meaning set forth on Exhibit D. 
  
 1.16 “Control” means, with respect to any intellectual property right or other intangible property, that a Party or one of its
Affiliates owns or has a license or sublicense to such item or right, and has the ability to grant access, license or sublicense in or to such right without violating the terms of any agreement or other arrangement with any Third Party. 

 
 1.17 “Cost of Goods” has the meaning as set forth
in Exhibit A. 
  
 1.18
“Development” means all activities relating to obtaining Regulatory Approval of a Collaboration Product, including all test method development, stability testing, toxicology, formulation, process development, cGMP audits (but
only those performed prior to Regulatory Approval and excluding any audits for commercial Manufacture), cGLP audits, cGCP audits, validation, quality assurance/quality control development, preclinical and clinical testing and studies, regulatory
affairs and outside counsel regulatory legal services relating to any of the foregoing, and any activities relating to the Manufacture of Collaboration Products other than commercial quantities thereof. For the avoidance of doubt, the conduct of
Phase III-B Clinical Studies will be considered Development. 
  
 1.19 “Development Expenses” means the expenses incurred by a Party that are consistent with a Development Plan and are specifically attributable or reasonably allocable to the Development of a Collaboration Product.
Development Expenses shall include, but are not limited to, the following costs incurred for the Development of a Collaboration Product: the cost of studies on the toxicological, pharmacokinetic, metabolic or clinical aspects of a Collaboration
Product directed to obtaining Regulatory Approval of a Collaboration Product; the cost of Phase 

  

 - 3 - 

 
III-B Clinical Trials, and costs (and related fees) for preparing, submitting, reviewing or developing data or information for the purpose of submission to a
Governmental Authority to obtain Regulatory Approval of a Collaboration Product; and manufacturing process development and scale-up for Collaboration Products in bulk and finished form. Development Expenses shall exclude any [*] incurred by a
Party in connection with the Development of a Collaboration Product. 
  
 1.20 “Diligent Efforts” means the carrying out of obligations or tasks consistent with the reasonable best practices of the pharmaceutical industry for the development or commercialization of a pharmaceutical product
having similar market potential, profit potential or strategic value as the applicable Collaboration Product, based on conditions then prevailing. Diligent Efforts requires that the Party, at a minimum: (a) determine the general industry practices
with respect to the applicable activities; (b) reasonably promptly assign responsibility for such obligations to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis; (c) set and consistently seek
to achieve specific and meaningful objectives for carrying out such obligations; and (d) make and implement decisions and allocate resources designed to advance progress with respect to such objectives. 
  
 1.21 “Drug Approval Application” means an application
for Regulatory Approval required before commercial sale or use of a Collaboration Product as a drug in a regulatory jurisdiction, including a new drug application (“NDA”) or supplemental new drug application
(“SNDA”) or any amendments thereto submitted to the FDA. 
  
 1.22 “FDA” means the United States Food and Drug Administration or any successor federal agency thereto. 
  

1.23 “Field” means all human and veterinary pharmaceutical uses. 
  
 1.24 “First Commercial Sale” means, with respect to a Collaboration Product and on a
country-by-country basis, the first commercial sale after receipt of Regulatory Approval of such Collaboration Product in such country. Sales for clinical studies, compassionate use, named patient programs, sales under a treatment IND, test
marketing, any nonregistrational studies, or any similar instance where the Collaboration Product is supplied with or without charge shall not constitute a First Commercial Sale. 
  
 1.25 “Generic Product” means, with respect to a Collaboration Product and on a country-by-country
basis, a product that includes an active ingredient that is the same as the Compound, including without limitation, any product which is submitted for Regulatory Approval through an abbreviated NDA (“ANDA”), an application under
Section 505(b)(2) of the Act or foreign equivalent of the foregoing that references any NDA or SNDA or any foreign equivalent thereof for the Collaboration Product. 
  
 1.26 “Governmental Authority” means any court, tribunal, arbitrator, agency, legislative body,
commission, official or other instrumentality of (i) any government of any country, (ii) a federal, state, province, county, city or other political subdivision thereof or (iii) any supranational body, including without limitation the European
Agency for the Evaluation of Medicinal Products. 
  

 - 4 - 

 1.27 “Improvement” means any enhancement or modification of (i) a Collaboration
Product, (ii) the Compound’s or Collaboration Product’s use, dosage form, indication, line extension, presentation or formulation or (iii) the process or method for the Manufacture of the Compound or Collaboration Product, in each case
whether or not patentable, that is developed by or for, invented or acquired by, or comes under the Control of, New River or Shire during the Term. 
  
 1.28 “IND” means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable
Regulatory Authority outside of the United States such as a clinical trial application (CTA) or a clinical trial exemption (CTX). 
  
 1.29 “Invention” means any discovery (whether patentable or not) conceived during the Term and potentially useful for the
Manufacture, use, Development or Commercialization of the Compound or a Collaboration Product. 
  
 1.30 “Joint Invention” means an Invention that is conceived jointly by an employee of, or person under an obligation of assignment to, each of New River and Shire. 
  
 1.31 “Know-How” means any non-public information,
results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, ideas, discoveries, inventions, trade secrets, practices, methods, tests, assays, techniques, specifications, processes,
formulations, formulae, knowledge, know-how, skill, experience, materials, including pharmaceutical, chemical and biological materials, products and compositions, scientific, technical or test data (including pharmacological, biological, chemical,
biochemical, toxicological and clinical test data), analytical and quality control data, stability data, studies and procedures, drawings, plans, designs, diagrams, sketches, technology, documentation, and patent-related and other legal information
or descriptions. 
  
 1.32 “Law” or
“Laws” means all laws, statutes, rules, codes, regulations, orders, judgments and/or ordinances of any Governmental Authority. 
  
 1.33 “Licensed Know-How” means all Know-How that is Controlled by New River as of the Effective Date or at any time during the
Term and that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or a New River Invention; provided, however, that Know-How Controlled by New River disclosing New
River’s proprietary CarrierwaveTM technology shall not be included in Licensed Know-How except to the extent
necessary for Shire to exercise its rights and perform its obligations under this Agreement. Notwithstanding anything herein to the contrary, Licensed Know-How shall exclude Licensed Patents. 
  
 1.34 “Licensed Patent” means a Patent that (i) claims
the Manufacture, use, Development, Commercialization and/or export of the Compound, a Collaboration Product and/or a New River Invention, and (ii) is Controlled by New River as of the Effective Date or at any time during the Term. For the avoidance
of doubt, all New River Collaboration Patents shall be considered Licensed Patents. 
  
 1.35 “Losses” means any and all amounts paid or payable to Third Parties with respect to a Third Party Claim, including without limitation, damages (including all incidental and 

  

 - 5 - 

 
consequential damages), deficiencies, defaults, awards, settlement amounts, assessments, fines, dues, penalties, costs, liabilities, obligations, taxes,
liens, losses, lost profits, fees and expenses (including, without limitation, court costs, interest and reasonable fees of attorneys, accountants and other experts). 
  
 1.36 “Major EU Market” means each of France, Germany, the United Kingdom, Italy and Spain.

  
 1.37 “Manufacture” means all
activities related to the manufacturing of a pharmaceutical product, or any ingredient thereof, including but not limited to manufacturing Compound or supplies for Development, manufacturing Collaboration Product for commercial sale, packaging,
in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the
foregoing. 
  
 1.38 “Net Sales” means,
with respect to a Collaboration Product, the amount invoiced by Shire, its Affiliates or sublicensees for sales of such Collaboration Product to a Third Party (“Invoiced Amount”) less: (i) transportation charges, freight and
insurance (but only insurance related to protecting the particular shipment against physical loss or damage); (ii) taxes (other than taxes based on income), tariffs, customs duty, excise or other duty and any other governmental charges, all to the
extent imposed upon the sale, transportation or delivery of such Collaboration Product and paid by the seller; (iii) Third Party distributor fees; (iv) trade discounts, quantity discounts, cash discounts, rebates, reimbursements, cooperative
advertising allowances, credits or chargebacks actually granted, allowed or incurred in the ordinary course of business in connection with the sale of such Collaboration Product, including any credits, volume rebates, charge-back and prime vendor
rebates, fees, fees for services, reimbursements or similar payments granted or given to wholesalers and other distributors, buying groups, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations or
other institutions or health care organizations; (v) adjustments, allowances or credits (calculated on a per unit basis) to customers, not in excess of the selling price per unit of such Collaboration Product, including without limitation on account
of price adjustments, governmental requirements, billing errors, rejection, damage, recalls or return of such Collaboration Product; (vi) payments or rebates paid in connection with sales of Collaboration Products to any governmental or regulatory
authority in respect of any state or federal Medicare, Medicaid or similar programs; (vii) royalties or technology access fees paid to a Third Party in respect of the sale of such Collaboration Product; (viii) write-offs for bad debts incurred (net
of any bad debts later recovered); and (ix) any item substantially similar in character/substance to the foregoing. Net Sales shall be accounted for in accordance with generally accepted accounting principles (“GAAP”) consistently
applied in the jurisdiction in which the sales occur, it being understood that bad debt write-off shall be deducted in arriving at Net Sales notwithstanding that such treatment may be inconsistent with GAAP, and it being further understood that
Shire shall make bad debt write-off decisions consistent with its usual business practices. 
  
 For the purposes of determining Net Sales in the ROW Territory with respect to a Collaboration Product that (x) is sold as a Combination Product and (y) is also sold in the US Territory, the Net Sales in the ROW
Territory of any such Combination Product shall be determined by deducting 

  

 - 6 - 

 
from the Invoiced Amount the fully loaded acquisition cost per unit of the other active ingredient(s) included in such Combination Product. 
  
 For the purposes of determining Net Sales in the ROW Territory with respect to a
Collaboration Product that (x) is sold as a Combination Product and (y) is not also sold in the US Territory, the Net Sales in the ROW Territory of any such Combination Product shall be determined in any accounting period by multiplying the Net
Sales in the ROW Territory of the Combination Product by the fraction A/(A+B), where A is the average Invoiced Amount per unit of the Collaboration Product when sold as a stand-alone Collaboration Product in finished form in the applicable country
in the ROW Territory and B is the average invoice price of the other product(s) sold as stand-alone product(s) in finished form in the applicable country in the ROW Territory. In the event that such average Invoiced Amount or average invoice price,
as applicable, cannot be determined for the Collaboration Product or the other product(s), Net Sales in the applicable country in the ROW Territory for purposes of determining royalties shall be mutually agreed by the Parties based on the relative
value contributed by each component. 
  
 In addition, Net Sales in the ROW
Territory shall be determined without regard to the deduction for royalties or technology access fees provided for in clause (vii) above to the extent that (1) such royalties or technology access fees constitute Third Party Royalties and (2) the
royalties payable by Shire to New River in respect of such Net Sales in the ROW Territory have been reduced by such Third Party Royalties in accordance with Section 10.5.1(a). 
  
 Notwithstanding the foregoing, in the ROW Territory, the disposition of a Collaboration Product or the use of the Collaboration Product
without charge in excess of costs, including by means of clinical studies, compassionate use, named patient programs, sales under a treatment IND, test marketing, any nonregistrational studies, patient assistance program, or any similar instance
where the Collaboration Product is supplied without charge in excess of costs shall not result in any Net Sales. Additionally, amounts received by Shire or its Affiliates or sublicensees for the sale of Collaboration Products among Shire and its
Affiliates and sublicensees for resale shall not be included in the computation of Net Sales hereunder. For the avoidance of doubt, no amount of cost, expense or other reduction or adjustment, whether or not specifically referred to in this
definition of Net Sales, shall serve to adjust the Invoiced Amount more than once in arriving at Net Sales. 
  
 1.39 “New River Invention” means an Invention that is conceived, solely or jointly with a Third Party, by an employee of New River
or a person under an obligation of assignment to New River. 
  
 1.40 “Patent” means (i) valid and enforceable patents, re-examinations, reissues, renewals, extensions, supplementary protection certificates and term restorations, any confirmation patent or registration patent or
patent of addition based on any such patent, (ii) pending applications for patents, including without limitation continuations, continuations-in-part, divisional, provisional and substitute applications, and inventors’ certificates, (iii) all
foreign counterparts of any of the foregoing, and (iv) all priority applications of any of the foregoing. 
  

 - 7 - 

 1.41 “Patent Expenses” means the fees and expenses of outside counsel and
payments to Third Parties incurred after the Effective Date in connection with the preparation, filing, prosecution and maintenance of the Licensed Patents, the Joint Collaboration Patents, and the Shire Patents covering Compound and Collaboration
Products, including the costs of patent interference and opposition proceedings, net of any reimbursement of such expenses by Third Parties. 
  
 1.42 “Person” means any natural person, corporation, firm, business trust, joint venture, association, organization, company,
partnership or other business entity, or any government, or any agency or political subdivisions thereof. 
  
 1.43 “Phase III-B Clinical Trials” means product support clinical trials of a Collaboration Product (i.e., a clinical trial
which is not required for receipt of initial Regulatory Approval but which may be useful in providing additional drug profile data or in seeking a label expansion) commenced before receipt of Regulatory Approval for the indication for which such
trial is being conducted. For the avoidance of doubt, Phase III-B Clinical Trials shall be considered part of Development. 
  
 1.44 “Promotional Materials” means all written, printed, video or graphic advertising, promotional, educational and communication
materials (other than Collaboration Product labels and package inserts) for marketing, advertising and promotion of the Collaboration Products, including, without limitation, copyrights in any such materials and all designs, industrial designs,
design patents, design registrations, and design patent applications developed in connection with such materials, for use by (a) a sales representative or (b) advertisements, web sites or direct mail pieces. For clarity, it is understood and agreed
that Promotional Materials shall not include corporate communications and general marketing or advertising by a Party or its Affiliate; provided, however, that to the extent that such corporate communications or general marketing or advertising
include or reference a Collaboration Product or related disease state and do not make any actual or implied claims, then such corporate communications or general marketing or advertising shall be governed by the provisions of Section 9.2.

  
 1.45 “Regulatory Approval” means all
approvals [*], product and/or establishment licenses, registrations or authorizations of any regional, federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacture, use, storage,
import, export, transport, offer for sale, or sale of a pharmaceutical product in a regulatory jurisdiction. 
  
 1.46 “ROW Territory” means the world, excluding the US Territory. 
  
 1.47 “Shire Background Know-How” means all Know-How Controlled by Shire, other than Shire
Collaboration Know-How, that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or Shire Invention. Notwithstanding anything herein to the contrary, Shire Background
Know-How shall exclude Shire Background Patents. 
  

 - 8 - 

 1.48 “Shire Background Patent” means a Patent Controlled by Shire, other than a
Shire Collaboration Patent, that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or Shire Invention. 
  
 1.49 “Shire Collaboration Know-How” means all Know-How that is developed by Shire or its Affiliates
during the Term pursuant to this Agreement or the US Agreement and that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or Shire Invention. Notwithstanding anything
herein to the contrary, Shire Collaboration Know-How shall exclude Shire Collaboration Patents. 
  
 1.50 “Shire Invention” means an Invention that is conceived, solely or jointly with a Third Party, by an Affiliate or employee of
Shire or a person under an obligation of assignment to Shire. 
  
 1.51 “Shire Know-How” means the Shire Background Know-How and the Shire Collaboration Know-How. Notwithstanding anything herein to the contrary, Shire Know-How shall exclude Shire Patents. 
  
 1.52 “Shire Patents” means the Shire Background
Patents and the Shire Collaboration Patents. 
  
 1.53
“[*]” means [*]. 
  
 1.54
“Third Party” means any entity other than New River or Shire or their respective Affiliates. 
  
 1.55 “US Territory” means the United States of America, its territories and possessions. 
  
 1.56 “Valid Claim” means: (a) a claim of an issued
Patent that has not (i) expired or been canceled, (ii) been declared invalid or unenforceable by a decision of a court or other appropriate body of competent jurisdiction, from which no appeal is or can be taken, (iii) been admitted to be invalid or
unenforceable through reissue, disclaimer or otherwise, or (iv) been abandoned, disclaimed or dedicated to the public; and (b) a claim included in a pending patent application that is being actively prosecuted in accordance with this Agreement and
that has not been (i) canceled, (ii) withdrawn from consideration, (iii) finally determined to be unallowable by the applicable governmental authority (from which no appeal is or can be taken), or (iv) abandoned or disclaimed. Notwithstanding the
foregoing clause (b), in the event that a pending claim in a pending patent application is rejected and does not issue in an issued Patent within [*] after the earliest date from which such claim was originally presented, such a pending claim
will not be a Valid Claim, unless and until such pending claim subsequently issues in an issued Patent, at which time such claim may again be a Valid Claim as of the date of issuance of such Patent, if such claim also meets the requirements of this
Section 1.56. 
  
 Interpretation. Unless the context of this Agreement
otherwise requires, (a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,”
and other similar words refer to this entire Agreement; and (d) the terms “Article” and “Section” refer to 

  

 - 9 - 

 
the specified Article and Section of this Agreement. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer
to calendar days. 
  
 Additional Definitions. Each of the following
definitions is set forth in the Section of this Agreement indicated below: 
  

			
	 Definition

	  	 Section

	Agreement	  	Preamble
	ANDA	  	Section 1.25
	Breaching Party	  	Section 12.2.1
	Confidential Information	  	Section 9.1.1
	Contractors	  	Section 11.1.3(d)(i)
	Development Plan	  	Section 3.2.1
	Disclosing Party	  	Section 9.1.1
	Dollars	  	Section 16.7
	Effective Date	  	Recitals
	Existing NDA	  	Section 9.6
	GAAP	  	Section 1.38
	Hatch-Waxman Certification	  	Section 10.6
	Indemnification Claim Notice	  	Section 14.2
	Indemnified Party	  	Section 14.2
	Indemnifying Party	  	Section 14.2
	Indemnitee	  	Section 14.2
	Indemnitees	  	Section 14.2
	Invoiced Amount	  	Section 1.38
	January Agreement	  	Recitals
	JDC	  	Section 2.2.1
	JIPC	  	Section 2.4.1
	Joint Collaboration Patents	  	Section 10.1.1
	Joint Press Release	  	Section 9.2
	JSC	  	Section 2.3.1
	Material Breach	  	Section 12.3.1
	NDA	  	Section 1.21
	New River	  	Preamble
	New River Collaboration Patents	  	Section 10.3.1
	New River Marks	  	Section 10.9.3
	Notice of Termination For Material Breach	  	Section 12.3.3
	Notifying Party	  	Section 12.2.1
	Parties	  	Preamble
	Party	  	Preamble
	[*]	  	Section 8.8
	Prior Consultants	  	Section 9.6
	Purchase Interest	  	Section 12.3.5(a)
	Purchase Notice	  	Section 12.3.5
	Purchase Price	  	Section 12.3.5(a)

  

 - 10 - 

			
	 Definition

	  	 Section

	Receiving Party	  	Section 9.1.1
	Recovery	  	Section 10.5.2(c)(iv)
	Representatives	  	Section 15.1
	Shared Expenses	  	Section 3.5.1
	Shire	  	Preamble
	Shire Collaboration Patents	  	Section 10.3.2
	Shire Marks	  	Section 10.9.3
	SNDA	  	Section 1.21
	Term	  	Section 12.1
	Third Party Claim	  	Section 14.1.1
	Third Party Manufacturers	  	Section 2.3.2(a)
	Third Party Royalty	  	Section 10.5.1(a)
	US Agreement	  	Recitals
	Withholding Taxes	  	Section 7.5.1
	Working Group	  	Section 2.5.4
	$	  	Section 16.7

  
 ARTICLE 2

 MANAGEMENT OF COLLABORATION 
  
 2.1 General. The general purpose of the collaboration described in this Agreement will be to Develop and Commercialize Collaboration
Products. The Parties desire to establish three (3) specialized committees to oversee the Parties’ collaboration under this Agreement and to facilitate communications between the Parties with respect to the Development, Manufacturing and
intellectual property strategy of Collaboration Products hereunder and, where applicable, in the US Territory. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have
the obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. For the avoidance of doubt, the Committees described herein are the same
committees as are described in the US Agreement, and each such Committee will have the responsibilities and authority set forth in this Agreement and in the US Agreement. 
  
 2.2 Joint Development Committee (JDC). 
  
 2.2.1 Formation and Purpose. Promptly following the Effective Date, the Parties shall create a
joint development committee (the “JDC”) to oversee the Development of Collaboration Products hereunder. The purposes of the JDC shall be (a) to determine the Development strategy for the Collaboration Products in the US Territory
and Major EU Markets, (b) to facilitate the management and implementation of the Parties’ Development activities hereunder, and (c) to approve plans and budgets for the Development by New River of Collaboration Products for ADHD in the US
Territory. The JDC shall have the membership and shall operate by the procedures set forth in Section 2.5. 
  

 - 11 - 

 2.2.2 Specific Responsibilities of the JDC. In addition to its overall
responsibilities described in Section 2.2.1, subject to Section 2.6.1, the JDC shall, in particular: 
  
 (a) select Collaboration Products for research and Development under this Agreement in the US Territory and Major EU Markets;

  
 (b) prepare, approve and amend each
Development Plan (including regulatory submission strategies and plans) for Collaboration Products in the Major EU Markets; 
  
 (c) monitor the progress of the activities undertaken by the Parties pursuant to each Development Plan; 
  
 (d) review and approve proposals from the Parties to
Develop Improvements and/or Combination Products; 
  
 (e) coordinate and oversee the Parties’ Regulatory Approval submission plans in the US Territory; 
  
 (f) design and approve all clinical trials of Collaboration Products proposed to be conducted anywhere in the world for consistency
and efficiency, including without limitation by creating the protocols, defining the end points, and selecting the primary investigators for such trials; 
  
 (g) have primary responsibility for establishing the objectives for all Phase IV Clinical Trials of Collaboration Products proposed
to be conducted for the US Territory, including without limitation by creating the protocols, defining the end points, and selecting the primary investigators for such trials; 
  
 (h) manage the flow of information with respect to Development being conducted for each Collaboration
Product; 
  
 (i) review and approve the
statistical analysis plans and protocols for all Collaboration Product clinical studies conducted worldwide, and any investigator’s brochure(s) and revisions thereto; 
  
 (j) work together with the other Committees during the Development of Collaboration Products to
assure a smooth transition from Development of such Collaboration Product to Commercialization of such Collaboration Product; 
  
 (k) review and approve compliance plans whereby the Parties prepare for or participate in a Governmental Authority inspection of
the preclinical or clinical data or preclinical sites/clinical sites or laboratories; and 
  
 (l) review and approve pharmacovigilance plans. 
  

 - 12 - 

 2.3 Joint Supply Committee (JSC). 
  
 2.3.1 Formation and Purpose. Promptly after the Effective Date, the Parties shall create a
joint supply committee (the “JSC”) to facilitate the management and implementation of the Parties’ activities with regard to the Manufacture and supply of Collaboration Products worldwide. The JSC shall have the membership and
shall operate by the procedures set forth in Section 2.5. 
  
 2.3.2 Specific Responsibilities of the JSC. In addition to its overall responsibilities described in Section 2.3.1, and subject to the provisions of Section 2.6.1 and Article 5, the JSC shall, in
particular: 
  
 (a) select which Party
and/or Third Party(ies) to engage for the Manufacture and supply of Collaboration Products and components thereof (“Third Party Manufacturers”), oversee auditing of Third Party Manufacturers, and approve contracts governing such
Manufacture and supply; 
  
 (b) delineate
requirements and responsibilities for development and licensure of manufacturing processes and facilities for Collaboration Products and for worldwide supply of Collaboration Products; 
  
 (c) jointly develop a Manufacturing strategy for the ROW Territory to enable development and
licensure of manufacturing processes and facilities for Collaboration Products that includes all aspects of Manufacture and release, including but not limited to formulations, intermediate, dosage form, devices, product characterization studies,
test methods and process validation studies, stability studies and Manufacturing plans and forecasts and the implementation of Manufacturing Improvements; 
  
 (d) determine Manufacturing plans and budgets, including timelines and inventory strategies, and allocate responsibilities for and
oversee the implementation of such plans in accordance with this Agreement; 
  
 (e) oversee and approve process development plans prior to the Manufacture of registration batches of Collaboration Products; 
  
 (f) oversee and approve plans to support Manufacture of commercial supply of Compound and
Collaboration Products; 
  
 (g) review
quality assurance efforts, including but not limited to those efforts with respect to the establishment of specifications and quality standards for Collaboration Products; 
  
 (h) review and coordinate the drafting and contents of the Chemistry, Manufacturing and Controls
section of a Drug Approval Application for Collaboration Products; 
  
 (i) review and approve technology transfer plans for any changes in Manufacturing sites, testing sites, and responsibilities in the supply chain for Collaboration Products, it being understood that decisions
regarding the selection of which of a Party’s own Manufacturing and testing sites shall be used to manufacture any component of a Collaboration 

  

 - 13 - 

 
Product, if a Party Manufactures any component of a Collaboration Product pursuant to this Agreement or any related supply agreement, shall remain in the
sole control of such Party; 
  
 (j)
prepare for regulatory inspections and ensure adherence to compliance standards with respect to Collaboration Products; 
  
 (k) ensure that future logistical strategies and capacity planning are consistent with the forecasts provided for the US Territory
and the ROW Territory, as well as inventory levels for Collaboration Products; 
  
 (l) review quality-related issues concerning the Collaboration Products or any component thereof; and 
  
 (m) review and approve compliance plans whereby the
Parties prepare for or participate in a Governmental Authority inspection of the Manufacturing or testing site of the Compound. 
  
 2.4 Joint Intellectual Property Committee (JIPC). 
  
 2.4.1 Formation and Purpose. Promptly after the Effective Date, the Parties shall create a joint intellectual property
committee (the “JIPC”) to facilitate the exchange of information between the Parties to the extent required by this Agreement regarding the prosecution, maintenance and enforcement of the Licensed Patents, Licensed Know-How, Shire
Collaboration Patents, Shire Collaboration Know-How, and Joint Inventions. The JIPC shall have the membership and shall operate by the procedures set forth in Section 2.5. 
  
 2.4.2 Specific Responsibilities of the JIPC. In addition to its overall responsibilities
described in Section 2.4.1, subject to Section 2.6.3 and Article 10, the JIPC shall, in particular: 
  
 (a) Exchange information between the Parties regarding the Parties’ activities under this Agreement relating to the filing,
prosecution, maintenance and enforcement of the Licensed Patents, Licensed Know-How, Shire Collaboration Patents and Shire Collaboration Know-How; and 
  
 (b) Consult regarding the filing, prosecution, maintenance and enforcement of Joint Collaboration Patents and Joint Inventions.

  
 2.5 General Committee Membership and Procedures.

  
 2.5.1 Membership. For the
JDC, JSC and JIPC, each Party shall designate an equal number of representatives who are employees of such Party or an Affiliate of such Party (not to exceed three (3) for each Party) with appropriate expertise to serve as members of such Committee;
provided that a Party may designate outside legal counsel as a representative to the JIPC. Each representative may serve on more than one Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee
representatives at any time upon written notice to the other Party. Each Committee shall have co-chairpersons. New River and Shire shall each select from their representatives a co-chairperson for each of the Committees. 

  

 - 14 - 

 
The co-chairpersons of each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such
Committee, and preparing and issuing minutes of each meeting within thirty (30) days thereafter; provided, that a Committee co-chairperson shall call a meeting of the applicable Committee promptly upon the written request of the other co-chairperson
to convene such a meeting. Such minutes will not be finalized until both chairpersons review and confirm the accuracy of such minutes in writing. 
  
 2.5.2 Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings
be held less frequently than once every four (4) months. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences); provided, that at least one meeting per year will be held in person.
The Parties will alternate in designating the location for in-person meetings, with New River selecting the first meeting location. Other employees of each Party or any of its Affiliates involved in the Development, Manufacture or Commercialization
of Collaboration Products may attend meetings of such Committee as nonvoting participants, and, with the consent of each Party, consultants, representatives, or advisors involved in the Development, Manufacture or Commercialization of Collaboration
Products may attend meetings of such Committee as nonvoting observers; provided, that such Third Party representatives are under obligations of confidentiality and non-use applicable to the Confidential Information of each Party and that are at
least as stringent as those set forth in Article 9. Each Party shall be responsible for all of its own expenses of participating in any Committee (including without limitation in any Working Group). 
  
 2.5.3 Meeting Agendas. Each Party will
disclose to the other proposed agenda items along with appropriate information at least seven (7) Business Days in advance of each meeting of the applicable Committee; provided, that under exigent circumstances requiring Committee input, a Party may
provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such
agenda items or the absence of a specific agenda for such Committee meeting. 
  
 2.5.4 Working Groups. From time to time, each Committee may establish and delegate duties to other committees, sub-committees or directed teams (each, a “Working Group”) on an
“as-needed” basis to oversee particular projects or activities. Each such Working Group shall be constituted and shall operate as the JDC, JSC or JIPC, as the case may be, determines; provided that each Working Group shall have equal
representation from each Party. Working Groups may be established on an ad hoc basis for purposes of a specific project for the life of a Collaboration Product, or on such other basis as the applicable Committee may determine. Each Working Group and
its activities shall be subject to the oversight, review and approval of, and shall report to, the Committee that established such Working Group. In no event shall the authority of the Working Group exceed that specified for the relevant Committee
in this Article 2. 
  
 2.5.5
Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no
Committee shall have 

  

 - 15 - 

 
any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 16.1 below.

  
 2.6 Committee Decision-Making. Subject to the
terms of this Section 2.6, each Committee will take action by unanimous vote with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by a written resolution signed by the designated
representatives of each of the Parties. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to
the Chief Executive Officer of the other Party. The Chief Executive Officers (or their respective designees, provided that each such designee is not a member of the applicable Committee and occupies a position senior to the positions occupied by the
applicable Party’s members of such Committee) of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve
the dispute within thirty (30) days after submission of such dispute to such officers. If any such dispute is not resolved by the Chief Executive Officers or their designees within thirty (30) days after submission of such dispute to such officers,
then the Chief Executive Officer or designee of the Party specified in Section 2.6.1 or 2.6.12, as applicable, shall have the authority to finally resolve such dispute acting in good faith. 
  
 2.6.1 JDC Authority. 
  
 (a) If a dispute in the JDC is not resolved pursuant
to Section 2.6 above and such dispute relates primarily to the Development of Collaboration Products for ADHD in the US Territory (other than those relating to Phase IV Clinical Trials), the Required Studies or the [*], then the Chief Executive
Officer of [*] shall have the authority to finally resolve such dispute. 
  
 (b) Notwithstanding anything to the contrary in subsection (a): 
  
 (i) If a dispute in the JDC is not resolved pursuant to Section 2.6 above and such dispute (A) does
not relate primarily to any of the activities specified in subsection (a) above (including, without limitation [*] the [*] of [*] for [*] in the [*] or for any [*] in the [*] for [*] in the
[*] or [*] or (B) relates primarily to [*] other than the [*] by [*] pursuant to the [*] for which [*] has not [*] at the [*] or [*] the [*] to [*] of any [*]
or [*] in the [*], then the Chief Executive Officer of Shire shall have the authority to finally resolve such dispute. 
  
 (ii) If [*] for the first Collaboration Product for ADHD on or before [*], then, until such time as [*], the
Chief Executive Officer of [*] shall have the authority to finally resolve a dispute that relates primarily to the Development of Collaboration Products for ADHD in the US Territory. 
  
 2.6.2 JSC Authority. If a dispute in the JSC
is not resolved pursuant to Section 2.6 above, then the Chief Executive Officer of [*] shall have the authority finally resolve such dispute; provided, however, that with respect to any matter over which [*] has approval (or other
consent right) pursuant to Article 5 (including, without limitation, Exhibit B), such 

  

 - 16 - 

 
resolution shall require the approval (or other consent) of [*] as set forth in Article 5 (including, without limitation, Exhibit B).

  
 2.6.3 JIPC Authority. If a
dispute in the JIPC is not resolved pursuant to Section 2.6 above, then [*] shall have the authority to finally resolve such dispute. The JIPC shall not have decision making authority under this Agreement and any dispute in the JIPC shall be
resolved in accordance with the terms of Article 15. 
  
 2.6.4 Casting Vote. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this Section 2.6 in a manner that excuses such Party from any of its obligations specifically enumerated
under this Agreement. 
  
 ARTICLE 3 
 DEVELOPMENT AND REGULATORY RESPONSIBILITIES 
  
 3.1 Overview. Subject to the roles of the various Committees described in Article 2 and the terms of this Agreement, Shire will be primarily
responsible for the Development of Collaboration Products for any indications in the ROW Territory. 
  
 3.2 Development Plans. 
  
 3.2.1 Scope. The Development of each Collaboration Product in the Major EU Markets under this Agreement shall be governed by
a development plan (each, a “Development Plan”). Each Development Plan shall be developed in good faith in accordance with Shire’s standard practices with the overall objective of achieving the commercial potential of such
Collaboration Product. Each Development Plan shall describe the proposed overall program of Development for the Collaboration Product for each indication in each of the Major EU Markets, including preclinical studies, toxicology, formulation,
process development, clinical studies, pediatric exclusivity plans and regulatory plans and other elements of obtaining Regulatory Approval in each applicable country, as well as timelines to key Governmental Authority meetings, Drug Approval
Applications and Regulatory Approvals. Each Development Plan shall include a summary of estimated Development Expenses of the program expected during the Development process through obtaining Regulatory Approval for each proposed indication and
route of delivery, to the extent such expenses are to be shared by the Parties under the terms of this Agreement, and shall also include a detailed budget for all such shared Development activities proposed for the following calendar year.

  
 3.2.2 Preparation and Approval of
Development Plans for the Major EU Markets. The Development Plan for the Development by Shire of Collaboration Products for any indications in the Major EU Markets will be prepared by Shire and will be submitted to the JDC for review and
approval. 
  
 3.2.3 Updates to the
Development Plans. As early as necessary in each year beginning with the first full calendar year after the Effective Date, Shire shall update and prepare the Development Plan for any such Collaboration Product for the following calendar year to
take into account completion, commencement or cessation of Development activities not contemplated by the then-current Development Plan, and submit such proposed Development Plan to the JDC no later than September 30 of such year for review and
approval. 
  

 - 17 - 

 3.2.4 Diligence. In addition to the specific diligence obligations of Shire
pursuant to Section 3.4.1, Shire will use Diligent Efforts to carry out the activities for which it may agree to be responsible set forth in a Development Plan in the ROW Territory. 
  
 3.3 Regulatory Activities. 
  

3.3.1 New River shall permit Shire access to and grant Shire the right to reference and use, for purposes of the Collaboration
Products, all data, regulatory filings and regulatory communications associated with any submissions for Regulatory Approval or other issues associated with any Collaboration Product, that is or would be relevant to Shire’s Development or
Commercialization of a Collaboration Product in the ROW Territory. To the extent that any such data, regulatory filings or regulatory communications are held by a Third Party, then New River shall arrange direct access to the portions of such data,
regulatory filings or regulatory communications that are relevant to the activities of Shire that are contemplated by this Agreement. Any information obtained by a Party pursuant to this Section 3.3.1 shall be deemed Confidential Information for
purposes of Article 9. 
  
 3.3.2 Within
thirty (30) days after the Effective Date, New River shall provide to Shire copies of all substantive or material Manufacturing, pre-clinical and clinical data compiled as of the Effective Date with respect to the Collaboration Product, including
any final versions of any study reports and any drafts then-outstanding of any study reports. Thereafter, New River shall provide to Shire copies of all substantive or material Manufacturing, pre-clinical and clinical data compiled with respect to
the Collaboration Product as soon as reasonably practicable after such data or results become available or compiled, including any drafts and final versions of any study reports. All disclosures under this Section 3.3.2 shall be delivered in
electronic format. For clarity, New River shall not be required to disclose New River’s proprietary CarrierwaveTM technology under this Agreement, except to the extent necessary for Shire to exercise its rights and perform its obligations under this Agreement or as otherwise specifically provided in this Agreement. 
  
 3.4 Development in the ROW Territory for ADHD and Other Indications.

  
 3.4.1 Diligence. After
receipt of Regulatory Approval in the US Territory for the first Collaboration Product for ADHD, Shire will commence Diligent Efforts to Develop a Collaboration Product for ADHD in the Major EU Markets. Shire will use Diligent Efforts to carry out
the activities set forth in the Development Plan for Collaboration Products in each Major EU Market country where, [*], including preparing all reports necessary as part of a Drug Approval Application. 
  
 3.4.2 Costs of Development. Shire shall bear
all expenses that are related to Developing and obtaining Regulatory Approval of Collaboration Products in the ROW Territory, subject to the terms of Section 3.5.1 below. The Parties recognize that Shire may desire to conduct clinical trials of
Collaboration Products within the US Territory for the purpose of obtaining Regulatory Approval within the ROW Territory, and agree that, prior to receipt of Regulatory Approval in the US Territory, Shire may conduct such trials with New
River’s prior written consent, such consent not to be unreasonably withheld, conditioned, or delayed; provided, that Shire is solely responsible for all costs of conducting any such trials. 
  

 - 18 - 

 3.4.3 Regulatory Activities. 
  
 (a) Shire shall be responsible for preparing and
filing Drug Approval Applications and seeking Regulatory Approvals for Collaboration Products in the ROW Territory, including preparing all reports necessary as part of a Drug Approval Application. The Parties intend that [*] New River shall
be responsible for providing to Shire, in the Common Technical Document format (unless the FDA requires a different format or the Common Technical Document format would delay the filing of the Drug Approval Application), the data and information
required to be submitted to the FDA, and such additional data and information relating to the Development activities for which it was responsible, including all clinical trials performed by it and, if applicable, all manufacturing and controls
information. Shire shall be responsible for prosecuting all such Drug Approval Applications and shall have a right of cross-reference to the Drug Approval Applications filed by New River in the US Territory for such purpose. New River will take all
such reasonable actions to allow such cross-reference. New River shall have the right of cross-reference to all such Drug Approval Applications filed by Shire for the purpose of prosecuting Drug Approval Applications in the US Territory, and Shire
shall, or shall cause its Affiliates to, take all such reasonable actions to allow such cross-reference. 
  
 (b) In connection with all Drug Approval Applications being prosecuted by Shire hereunder, Shire agrees to provide New River with a
copy (which may be wholly or partly in electronic form) of all filings to regulatory agencies in each Major EU Market country that it makes hereunder. Within thirty (30) days following the end of each calendar quarter, Shire shall report to New
River regarding the status of each pending and proposed Drug Approval Application in the ROW Territory. 
  
 (c) In the event that Shire desires New River to participate in any meeting, discussion or substantive telephone conference call
with any Governmental Authority relating to any Drug Approval Application or Regulatory Approval for Collaboration Products in the ROW Territory, Shire shall provide New River with reasonable advance notice of any such meeting, discussion or
conference call and New River shall participate with Shire. Shire shall promptly furnish New River with copies of all substantive documents or correspondence Shire has had with or receives from any Governmental Authority in the Major EU Markets, and
contact reports concerning substantive conversations or substantive meetings with any Governmental Authority in the Major EU Markets, in each case relating to any Drug Approval Application or Regulatory Approval (including without limitation any
minutes from a meeting with respect thereto). 
  
 (d) Shire shall provide to New River, on a timely basis, copies of all material Manufacturing, pre-clinical and clinical data compiled in support of a Drug Approval Application in the ROW Territory for a Collaboration Product (but
excluding any such data to the extent relating to the Manufacture of the Compound). 
  
 (e) In the event that any Governmental Authority threatens or initiates any action to remove a Collaboration Product from the
market in the ROW Territory, Shire shall notify New River of such communication immediately, but in no event later than one (1) Business Day, after receipt by Shire. Shire shall consult with New River prior to initiating a 

  

 - 19 - 

 
recall or withdrawal of Collaboration Product in a Major EU Market; provided that the final decision as to whether to recall or withdraw a Product in the ROW
Territory shall be made by Shire in its sole discretion. In the event of any recall or withdrawal for Collaboration Products sold in the ROW Territory, Shire shall implement any necessary action. 
  
 3.4.4 Reporting. At each meeting of the JDC
and the JSC, each Party will present a report describing the Development and Manufacturing activities performed by such Party with respect to Collaboration Products in the ROW Territory since the last such report. 
  
 3.5 Shared Expenses. 
  
 3.5.1 Except as otherwise provided in Section 3.4.2,
any Development Expenses incurred by either Party that, as determined by the JDC, have worldwide application to the Development or Commercialization of the Collaboration Products will be borne [*] by Shire and [*] by New River,
regardless of whether such work is conducted inside or outside of the United States (“Shared Expenses”). For clarity, Shire may use in the ROW Territory the results of Development of the first Collaboration Products for ADHD in each
of Adults, Adolescents and Children, without charge, but Shire shall be solely responsible for the performance and cost of any additional studies for the ROW Territory that do not have application in the US Territory. 
  
 3.5.2 Quarterly Reconciliation of Development Expenses.

  
 (a) Each Party shall calculate and
maintain records of Shared Expenses incurred by it in accordance with procedures to be agreed upon between the Parties. 
  
 (b) Within five (5) Business Days following the end of each calendar quarter, Shire shall submit to New River a written report
setting forth in reasonable detail, separately with respect to each Collaboration Product, the Shared Expenses it has incurred in such calendar quarter. 
  
 (c) Within five (5) Business Days following the end of each calendar quarter, New River shall submit to Shire a written report
setting forth in reasonable detail, separately with respect to each Collaboration Product, the Shared Expenses it has incurred in such calendar quarter. 
  
 (d) Within twenty-five (25) days following the end of each calendar quarter, Shire shall submit to New River a written report
setting forth in reasonable detail the calculation of all Shared Expenses for each Collaboration Product, and the calculation of any net amount owed by New River to Shire or by Shire to New River, as the case may be, in order to ensure the
appropriate sharing of Shared Expenses in accordance with the provisions of Section 3.5. The net amount payable shall be paid by Shire or New River, as the case may be, within thirty five (35) days following the end of each calendar quarter;
provided, that, in the event of a dispute, the disputing Party shall pay the amount not in dispute and provide written notice within five (5) Business Days after receipt of the written report in question to the other, specifying such dispute and
explaining the basis of the dispute. New River and Shire shall promptly thereafter meet and negotiate in good faith a resolution to such dispute. If such dispute is not resolved within forty-five (45) days after delivery of a notice of dispute with
respect 

  

 - 20 - 

 
thereto to the other Party, the disputing Party may audit the other Party pursuant to the provisions of Section 7.6.2. 
  
 3.6 Use of Third Parties. Either Party may retain Third Parties
to perform Development activities, subject to the terms provided in this Section 3.6 and in Section 8.3. Each Party shall remain liable for the performance of its obligations hereunder which it delegates to such Third Parties. Any Third Parties
performing Development activities hereunder shall be subject to confidentiality and non-use obligations at least as stringent as those set forth in Article 9 and must comply with the terms of Article 10. 
  
 3.7 Assistance. Subject to the terms of this Article 3, each
Party agrees to provide the other with all reasonable assistance and take all actions reasonably requested by the other Party that are necessary or desirable to enable the other Party to comply with any Law applicable to the Collaboration Products,
including, but not limited to, meeting, reporting and other obligations to maintain and update any Regulatory Approvals for the Collaboration Products. 
  
 3.8 Compliance with Laws. Each Party or its permitted Third Party contractors shall perform its responsibilities under this Article 3,
including those set forth in a Development Plan, in accordance with all applicable Laws, including without limitation cGLPs, cGCPs (or their non-US equivalents) and cGMPs. 
  
 ARTICLE 4 
 COMMERCIALIZATION OF COLLABORATION PRODUCTS 
  
 4.1 Principles of Commercialization. Shire will be solely responsible for Commercializing Collaboration Products in the ROW Territory during the Term. 
  
 4.2 Sales and Distribution of Collaboration Products to Third Parties. 
  
 4.2.1 Terms of Sale to Third Parties. For each
Collaboration Product, including all Improvements and Combination Products, Shire shall be solely responsible for handling all returns, recalls, order processing, invoicing and collection, distribution, and inventory and receivables arising from
sales to Third Parties. New River may not accept orders from a Third Party for a Collaboration Product or make sales for its own account (except to Shire) or for Shire’s account. If New River receives any order for a Collaboration Product, it
shall refer such orders to Shire for acceptance or rejection. Subject to Section 4.2.2, Shire shall have the right and responsibility for establishing and modifying the terms and conditions with respect to the sale of all Collaboration Products in
the ROW Territory, including any terms and conditions relating to or affecting the price at which the Collaboration Products will be sold, discounts available to managed care providers, any discount attributable to payments on receivables,
distribution of the Collaboration Products, and credits, price adjustments, or other discounts and allowances to be granted or refused. 
  
 4.2.2 [*]. If Shire or its Affiliates or sublicensees sell a Collaboration Product to a Third Party, [*] and at a
[*] Shire or its Affiliates or sublicensees for sales of such Collaboration Product [*], then Shire [*] in respect of such sale. 
  

 - 21 - 

 4.3 Marketing Plans for ROW Territory. With respect to the ROW Territory, Shire will have
full authority and discretion over the content of any marketing plan. 
  
 4.4 Regulatory Obligations During Commercialization. 
  
 4.4.1 Shire Responsibilities. Shire will maintain all regulatory filings and Regulatory Approvals in the ROW Territory for each Collaboration Product Developed pursuant to this Agreement, including all
INDs and Drug Approval Applications. As between the Parties, Shire will be solely responsible for all activities in connection with maintaining Regulatory Approvals required for the Commercialization of Collaboration Product in the ROW Territory,
including communicating and preparing and filing all reports (including adverse drug experience reports) with the applicable Governmental Authorities, as described in further detail in Section 3.4.3. 
  
 4.4.2 Pharmacovigilance. Shire shall be
responsible for all processing of information related to any adverse events, including, without limitation, any information regarding such adverse events that is received from a Third Party, related to a Collaboration Product after the First
Commercial Sale of such Product. The Party conducting any clinical studies prior to such First Commercial Sale shall be responsible for all processing of information related to any adverse events associated with such studies. As soon as reasonably
practicable following the date of this Agreement, the pharmacovigilance departments of each of New River and Shire shall meet and determine the approach to be taken for the collection, review, assessment, tracking and filing of information related
to adverse events associated with the Products, consistent with the provisions of this Section 4.4.2. Such approach shall be documented in a separate and appropriate written pharmacovigilance agreement between each of New River and Shire. Shire
agrees to share relevant information it receives (either directly or indirectly) with New River in a timely manner so as to allow New River to comply with its responsibility to report pharmacovigilance information under this Section 4.4.2.

  
 4.5 Diligence in Commercialization. Shire will
use Diligent Efforts in each of the Major EU Markets to launch a Collaboration Product in each such country after receiving all Regulatory Approvals for such Collaboration Product in such country, and thereafter will use Diligent Efforts to
Commercialize the Collaboration Product in such country. 
  
 4.6 Cost of Commercialization. In the ROW Territory, Shire shall bear all costs in connection with the Commercialization of Collaboration Products. 
  
 4.7 Use of Third Parties. Shire may retain Affiliates and/or Third Parties to perform Commercialization
activities in the ROW Territory. Shire shall remain liable for the performance of its obligations hereunder that it delegates to such Affiliates and/or Third Parties. Shire covenants and agrees not to use any Third Parties to perform promotional
activities for Collaboration Products in the Major EU Markets without the prior written approval of New River, such approval not to be unreasonably withheld, conditioned, or delayed. If the Parties agree to engage any such Third Party sales force,
such Third Party sales force will be directed, trained and controlled by Shire. 
  

 - 22 - 

 4.8 Promotional Materials. 
  
 4.8.1 Creation of Promotional Materials. Shire will create and develop Promotional Materials
for the ROW Territory. To the extent that Shire describes in any item of the Promotional Materials New River’s CarrierwaveTM proprietary technology, Shire shall include in such Promotional Materials the New River trademark for such technology. New River hereby grants Shire a royalty-free license for such purpose. To the extent Shire shall include such
description and trademark in the Promotional Materials, Shire shall comply with New River’s then-current guidelines for trademark usage, a copy of which shall be provided to Shire from time to time. 
  
 4.8.2 Shire Ownership of Promotional
Materials. Shire shall own all right, title and interest in and to any Promotional Materials relating to the Collaboration Products, including without limitation applicable copyrights and trademarks, but excluding trademarks owned by New River
in accordance with Section 10.9, and New River hereby assigns all its right, title and interest to such Promotional Materials to Shire and agrees to execute all documents and take all actions as are reasonably requested by Shire to vest title to
such Promotional Materials in Shire. 
  
 4.8.3
Use of Promotional Materials Exclusively for Collaboration Products. The Promotional Materials, and any aspects of those uniquely tied to the Collaboration Products, shall be used exclusively in connection with the Collaboration Products
in accordance with the terms of this Agreement. 
  
 4.8.4 Retention of Rights. Shire and New River, or their respective Affiliates, shall retain, throughout the Term and following termination, all rights, including without limitation all copyrights and trademarks, to all of
their respective programs and materials in all formats (print, video, audio, digital, computer, etc.) regarding sales training, patient education and disease management programs owned by them as of the Effective Date or developed by them during the
Term but outside of this Agreement, regardless of the fact that such programs or materials are shared with the other Party, as well as any modifications of such programs or materials that they may develop in the future which are not specific to a
Collaboration Product. In accordance with Section 4.8.2, Shire shall own any such modifications specific to a Collaboration Product. 
  
 4.9 Compliance with Laws. Each Party or its permitted Third Party contractors shall perform its responsibilities under this Article 4 in
accordance with all applicable Laws. 
  
 ARTICLE 5

 MANUFACTURE OF COLLABORATION PRODUCTS 
  
 5.1 Manufacture and Supply. 
  
 5.1.1 Manufacturing Process. New River will use Diligent Efforts to develop a process for the Manufacture of bulk Compound
and to scale up such process to a level sufficient to Manufacture and supply clinical and commercial supplies of bulk Compound for the ROW Territory. New River will undertake such development in consultation with the JSC, including the preparation
of filings necessary to obtain Regulatory Approval for the Manufacture of bulk Compound for the ROW Territory and the selection of any Third Party Manufacturer. In 

  

 - 23 - 

 
the event that New River includes the filings referred to in this Section 5.1.1 in Drug Master Files in the US Territory, Shire may reference such Drug
Master Files for countries in the ROW Territory in which Shire seeks Regulatory Approval of Collaboration Products; provided, however, that Shire will provide New River with assistance as reasonably requested by New River, and at no cost to New
River, to ensure compliance with regulatory requirements in such countries. Once such filings are made, no changes to the process for the Manufacture of bulk Compound for the ROW Territory shall be made without the written consent of Shire, such
consent not to be unreasonably withheld, conditioned or delayed; provided that New River will not require the prior written consent of Shire to make changes related to the process for the Manufacture of bulk Compound for the ROW Territory hereunder
that are required by a Governmental Authority or applicable Law. New River’s retention of any Third Party Manufacturer to perform any activities under this Section 5.1.1 shall be subject to the prior written approval of Shire, not to be
unreasonably withheld, conditioned, or delayed. 
  
 All costs
related to the foregoing activities set forth in this Section 5.1.1 that are additional to any activities set forth in Section 6.1.1 of the US Agreement shall be charged by New River to Shire at [*] 
  
 5.1.2 Development Supply. New River will
Manufacture, or arrange for a Third Party Manufacturer to Manufacture, bulk Compound for Development activities to be performed by Shire under this Agreement. Any such supply will be provided by New River to Shire [*] (as determined in
accordance with Exhibit A). 
  
 5.1.3
Commercial Supply. New River will Manufacture, or arrange for a Third Party Manufacturer to Manufacture, bulk Compound for use in the Manufacture of Collaboration Products by Shire or, at Shire’s direction, by a Third Party. Any such
supply will be provided by New River to Shire [*] (as determined in accordance with Exhibit A). Shire will arrange for the Manufacture of Collaboration Products for sale in the ROW Territory using bulk Compound provided by New River
under this Section 5.1.3. 
  
 5.2 Specifications and
Terms of Supply; Multiple Sources. New River, in consultation with the JSC, shall establish the specifications, including any necessary documentation, certificates of analysis and test results, for the bulk Compound to be Manufactured under this
Article 5, in each case subject to the prior written approval of Shire, such approval not be unreasonably withheld, conditioned or delayed. If a Governmental Authority in a country of the ROW Territory has promulgated any Laws or guidance documents
that relate or will relate to the Manufacture of the Compound or a Collaboration Product that are different from those promulgated in the US Territory or the European Union, Shire shall notify New River of such Laws or guidance documents. The
Parties shall endeavor to maintain compatible specifications for bulk Compound on a worldwide basis, and to minimize the number of distinct specifications in different countries. New River shall establish at least [*] sources of supply for
bulk Compound to be Manufactured under this Article 5. 
  
 5.3
Manufacture by Shire; Commercial Supply by Shire. Shire will have the right to act as, or to appoint a Third Party to act as, a second source for Collaboration Products under terms and conditions to be established by the Parties and
subject to reasonable commercial qualification by New River and applicable regulatory requirements. In connection with such 

  

 - 24 - 

 
right, Shire will prepare all specifications required for any facility at which Shire intends to Manufacture, or have Manufactured, Collaboration Products,
including cGMP qualification guidelines, and any QA approved procedures to be followed during the qualification of such facility, all consistent with the specifications and procedures approved in any existing Regulatory Approval, in each case at
Shire’s sole expense. Following validation of such facility, the JSC will task Shire with the production of quantities of Collaboration Products at least sufficient for Shire to maintain such validation as a second source and such quantities
shall be available for distribution by Shire. In the event that [*] any agreement with a Third Party Manufacturer for the Manufacture of Compound or otherwise [*] such that there is a reasonable likelihood of insufficient quantities of
Compound to satisfy the need thereof for the Manufacture of Collaboration Products, then Shire shall be entitled, but not be required, to assume in whole or in part New River’s rights and related obligations under such agreement (to the extent
permissible thereunder) or otherwise direct the exercise of rights and performance of obligations by New River under such agreement, including the establishment of additional Third Party Manufacturers or Manufacture by Shire, in each case upon the
mutual agreement of the Parties, such agreement not to be unreasonably withheld, delayed or conditioned. In such event the Parties shall meet and confer to devise the most effective supply plan for the bulk Compound and/or Collaboration Products and
to consider amendments to this or other agreements, as necessary. 
  
 5.4 Supply Terms. The Parties, in consultation with the JSC, will establish the terms and conditions applicable to the supply of Compound by New River to Shire under this Article 5, and enter into an appropriate supply
agreement with respect thereto containing terms and conditions consistent with the terms of this Agreement, including without limitation, this Article 5 and at a minimum those terms and conditions as set forth on Exhibit B, to the extent New
River is able to obtain such terms from Third Party Manufacturers having used Diligent Efforts to do so. For the avoidance of doubt, such agreement will provide for the manufacture of bulk Compound only, notwithstanding the references in Exhibit
B to the manufacture of “Compound or Collaboration Product.” 
  
 ARTICLE 6 
 FINANCIAL TERMS 
  
 6.1 Licensing Fee. As partial payment for the rights and licenses granted by New River pursuant to this
Agreement, Shire shall pay to New River a license fee equal to $1,200,000 within ten (10) Business Days after the Effective Date. This fee shall be non-creditable and non-refundable against any future obligations of Shire under this Agreement,
subject to Section 12.6. 
  
 6.2 Milestone Payment.
Within [*] after the [*] Shire shall pay New River $5,000,000, which shall be non-creditable and non-refundable, subject to Section 12.6. For the avoidance of doubt, this milestone is paid only once regardless of the number of
[*] in which a [*]. 
  
 The milestone is to be paid only once
irrespective of the number of Collaboration Products Developed, Manufactured or Commercialized under this Agreement. 
  

 - 25 - 

 6.3 Royalties on Net Sales in ROW Territory. 
  
 6.3.1 Royalty Rates [*]. As further
consideration for New River’s grant of the rights and licenses to Shire hereunder, subject to the adjustments provided for in Section 6.3.3, Shire will pay, or cause to be paid, to New River, on a Collaboration Product-by-Collaboration Product
basis, a royalty equal to: 
  
 (a)
[*] of aggregate Net Sales of such Collaboration Product [*], for that portion of the total amount of aggregate Net Sales of such Collaboration Product [*] in any calendar year that is less than or equal to [*];

  
 (b) [*] of aggregate Net Sales
of such Collaboration Product [*], for that portion of the total amount of aggregate Net Sales of such Collaboration Product [*] in any calendar year that is greater than $[*] but less than or equal to $[*]; 

 
 (c) [*] of aggregate Net Sales of such
Collaboration Product [*] for that portion of the total amount of aggregate Net Sales of such Collaboration Product [*] in any calendar year that exceeds [*]. 
  
 6.3.2 [*]. As further consideration for New River’s grant of the rights and licenses to
Shire hereunder, subject to the adjustments provided for in Section 6.3.3, Shire will pay, or cause to be paid, to New River a royalty equal to [*] of Net Sales of each Collaboration Product in the [*] 
  
 6.3.3 Royalty Rate Adjustment. The rates set
forth in Sections 6.3.1 and 6.3.2 shall be reduced by [*] (to [*]%, [*]%, and [*]%, and [*]%, respectively) with respect to Net Sales of a Collaboration Product in a particular country in which, and during such
time as, a Generic Product of such Collaboration Product has been launched and is then offered for sale by a Third Party in such country. 
  
 6.3.4 Royalty Term. Royalties due under Sections 6.3.1 and 6.3.2 will commence upon the First Commercial Sale of a
Collaboration Product in a particular country in the ROW Territory and will expire on a country-by-country basis upon the later of: (a) the expiration of the last-to-expire Licensed Patent containing a Valid Claim that would be infringed by the
Manufacture, use, or sale of the Collaboration Product in such country by an unlicensed Third Party if such unlicensed Third Party were to Manufacture the Collaboration Product in such country of Manufacture, or use or sell the Collaboration Product
in such country of sale, and (b) [*] from the First Commercial Sale of the Collaboration Product in such country. 
  
 ARTICLE 7 
 PAYMENT TERMS

  
 7.1 Payment Method. All amounts due to
either Party hereunder will be paid in United States Dollars by wire transfer in immediately available funds to an account designated by such Party. Any payments or portions thereof due hereunder that are not paid by the date such payments are due
under this Agreement will bear simple interest at the lower of (a) [*] [*] the US Prime Rate, as reported in the Wall Street Journal, Eastern Edition, on the due date (or, if the due date is not a business day, on the last
business day prior to such due date), or (b) the maximum rate permitted by applicable Law, calculated on the number of days such payment is delinquent; provided that such interest shall not be due to the extent that a payment is 

  

 - 26 - 

 
inadvertently paid late (e.g., if such late payment is accompanied by reasonable evidence that the payor was not aware of the due date of the payment
or reasonable explanation that such payment due date was unintentionally missed) and if the payor acts in good faith in making payment as soon as it discovers that a required payment has not been made. 
  
 7.2 Payment Schedules; Reports. The payments due pursuant to
Sections 3.5.2, 6.1, 6.2 and 10.3.5 are due and payable on the dates described therein. Royalty payments due pursuant to Section 6.3 are due and payable within thirty-five (35) days of the end of each calendar quarter during the Term during which
there were Net Sales of Collaboration Products in the ROW Territory. Shire will accompany each payment of royalties under this Agreement with a report setting forth, on a country-by-country basis, the amount of gross sales of each Collaboration
Product in such country, a calculation of Net Sales, the currency conversion rate used and the United States Dollar-equivalent of such Net Sales, and a calculation of the amount of royalty payment due on such Net Sales. Such report will be
considered Confidential Information of Shire subject to the obligations of Article 9 of this Agreement. The Parties acknowledge that any expenses or costs reported or shared in any way under this Agreement may be based upon estimates, which
estimates will be GAAP-compliant; provided that when the actual results become known relative to any estimated amount, any difference between the actual results and the estimate is reported and the next payment due hereunder related to such
estimated item is appropriately adjusted for such difference. The Parties acknowledge and agree that any reports and payments relating to any cost, expense, or other financial amount shared pursuant to this Agreement for the fourth quarter of any
calendar year shall reflect year-end reconciliations and adjustments, if any, applicable to the previous three quarters’ reported results. 
  
 7.3 Currency Conversion. For any currency conversion required in determining the amount of royalties due hereunder, such conversion will be
made at the exchange rate used by Shire, consistent with its general internal corporate policies as they relate to its income statement, for its own consolidation purposes for the translation of such currency into United States Dollars for any
royalty payments due pursuant to this Agreement. Such policies will be made available to New River upon request and will be consistent with customary industry practices. 
  
 7.4 Legal Restrictions. If at any time legal restrictions prevent the remittance by Shire of all or any part
of royalties on Net Sales in any country, Shire will have the right and option to make such payment by depositing the amount thereof in local currency to an account in the name of New River in a bank or other depository in such country. Shire will
consult with New River regarding, and promptly notify New River of, any and all such arrangements. 
  
 7.5 Taxes. 
  
 7.5.1 Withholding Taxes. New River will be responsible for any and all income or other taxes owed by New River and required
by applicable Law to be withheld or deducted from any of the royalty and other payments made by or on behalf of Shire to New River hereunder (“Withholding Taxes”), and Shire may deduct from any amounts that Shire is required to pay
hereunder an amount equal to such Withholding Taxes; provided, however, that if New River is not able to claim a credit or reimbursement for such tax, in whole or in part, as a result of Shire being a non-US entity, then Shire will deduct
Withholding Taxes in accordance with this Section 7.5.1, but will, in addition to the sums otherwise payable under this Agreement, 

  

 - 27 - 

 
pay to New River such further sum as will ensure that, after deduction of Withholding Taxes on all such sums, the net amount received by New River equals the
amount that New River would have received had the non-creditable or non-reimbursable excess portion of such additional Withholding Taxes not been deducted. Shire will provide New River with reasonable advance notice of tax withholding obligations to
which it reasonably believes that it is subject. New River will provide Shire any information available to New River that is necessary to determine the Withholding Taxes. Such Withholding Taxes will be paid to the proper taxing authority for New
River’s account and evidence of such payment will be secured and sent to New River within one (1) month of such payment. The Parties will do all such lawful acts and things and sign all such lawful deeds and documents as either Party may
reasonably request from the other Party to enable New River and Shire or its Affiliates or sublicensees to take advantage of any applicable legal provision or any treaty provisions with the object of paying the sums due to New River hereunder with
the lowest legal amount of Withholding Taxes. 
  
 7.5.2 Additional Withholding Taxes. If, as a result of any change in the corporate status or location of Shire, or the permitted assignment of this Agreement by Shire, additional Withholding Taxes become due on payments from
Shire or its permitted assignee to New River that would not have been due absent such change in corporate status or location or permitted assignment, and New River is not able to claim a credit or reimbursement for such tax, in whole or in part,
then Shire will deduct Withholding Taxes in accordance with this Section 7.5, but will, in addition to the sums otherwise payable under this Agreement, pay to New River such further sum as will ensure that, after deduction of Withholding Taxes on
all such sums, the net amount received by New River equals the amount that New River would have received had the non-creditable or non-reimbursable excess portion of such additional Withholding Taxes not been deducted. To the extent that any such
amount paid by Shire to New River in accordance with this Section 7.5 is in fact subsequently able to be claimed by New River as a credit or reimbursement for such tax otherwise deducted, then New River will repay such amount to Shire. 

 
 7.6 Records Retention; Audit. 
  
 7.6.1 Record Retention. Each Party will
maintain complete and accurate books, records and accounts used for the determination of expenses incurred in connection with the performance of Development or Commercialization activities or otherwise relevant for the calculation of Net Sales, in
sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records and accounts will be retained by such Party for three (3) years after the end of the period to which such books, records and accounts
pertain, or longer as is required by applicable Law. 
  
 7.6.2 Audit. Each Party will have the right to have an independent certified public accounting firm of internationally recognized standing, reasonably acceptable to the other Party, to have access during normal business hours,
and upon reasonable prior written notice, to such of the records of the other Party as may be reasonably necessary to verify the accuracy of any expenses shared or paid by the other Party under this Agreement or the calculation of Net Sales for any
calendar year ending not more than three (3) years prior to the date of such request; provided, however, that, no Party will have the right to conduct more than one such audit in any twelve (12) month period and that the auditing Party shall not be
permitted to audit the same 

  

 - 28 - 

 
period of time more than once, unless evidence of fraud or gross negligence arises in a subsequent audit and the auditing Party reasonably believes that such
evidence indicates the reasonable possibility of fraud or gross negligence in any such prior period. The accounting firm will disclose to the Parties only whether the various expenses subject to being shared by this Agreement or Net Sales reported
by the audited Party are correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than
[*], in which case the audited Party will bear the cost of the audit. If the audited Party disputes the findings pursuant to this Section 7.6.2, the Parties shall meet and discuss such dispute. If such dispute is not resolved within
forty-five (45) days, then it shall be subject to Article 15. Shire shall use Diligent Efforts to obtain from any sub-licensee audit rights at least as favorable as the audit rights set forth in this Section 7.6.2 and the right to share the results
of any such audit with New River. In the event that New River reasonably believes that there is a material inaccuracy in the reporting by a sub-licensee of the Net Sales of such sub-licensee, then New River may direct Shire to exercise such audit
rights in accordance with procedures reasonably requested by New River. New River shall succeed to the rights and obligations of Shire in respect of any costs or expenses associated with a sub-licensee audit requested by New River. 
  
 7.6.3 Payment of Additional Amounts. If, based
on the results of any audit, additional payments are owed to either Party under this Agreement, then the paying Party will make such additional payments within five (5) Business Days after the accounting firm’s written report is delivered to
the Parties. The provisions of Section 7.1 shall apply to such payment. 
  
 7.6.4 Confidentiality. Each Party will treat all information subject to review under this Section 7.6 in accordance with the provisions of Article 9. Prior to conducting any audit hereunder, the Party
conducting such audit will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such accounting firm to maintain all such financial information in confidence with standards no
less stringent that the terms of this Article 9 of this Agreement. 
  
 ARTICLE 8 
 LICENSES 
  
 8.1 Licenses to Shire. Subject to the terms of this Agreement, New River hereby grants to Shire an exclusive license, with the right to
grant sublicenses as provided in Section 8.3, under the Licensed Patents, the Licensed Know-How and New River’s interest in any Joint Collaboration Patents to (a) Develop and use Collaboration Products for Commercialization in the Field in the
ROW Territory and to Commercialize Collaboration Products in the Field in the ROW Territory, and (b) to make bulk and finished Collaboration Products (but not the Compound, except as otherwise provided in Article 5) for Commercialization in the
Field in the ROW Territory. Notwithstanding the foregoing, New River shall retain the co-exclusive right under the Licensed Patents, Licensed Know-How and New River’s interest in any Joint Collaboration Patents in the ROW Territory for the
purpose of research and Development of Collaboration Products in the Field in accordance with a Development Plan. 
  

 - 29 - 

 8.2 Licenses to New River. Subject to the terms of this Agreement, Shire hereby grants to
New River an exclusive (except as to Shire), paid-up license, without the right to grant sublicenses (except to Affiliates of New River), under the Shire Patents and Shire Know-How solely to conduct Development and Commercialization of Collaboration
Products in the Field in the US Territory pursuant to the US Agreement, and to supply Shire Collaboration Products and Compound for the ROW Territory in accordance with the terms of this Agreement. 
  
 8.3 Sublicensing. Shire may grant sublicenses under Section
8.1: [*]; provided, however, that the Development activities undertaken by any sublicensee of such rights will be subject to the oversight and authority of the JDC. The entry by Shire into a sublicense shall not relieve Shire of its
obligations under this Agreement, including the obligation to report the Net Sales of such sublicensee. 
  
 8.4 Scope of Licenses. As used in this Article 8, a license that is “exclusive except as to” the granting Party means that the
Party granting the license shall not grant any other entity (other than its Affiliates) any license under such patent rights with the right to practice within the Field, but that otherwise the granting Party retains all its rights of ownership in
such licensed rights, including without limitation the right to practice such patent rights, subject only to the license granted. 
  
 8.5 No Implied Licenses. Except as expressly provided in this Agreement, neither Party grants to the other Party any right or license in any
intellectual property right, whether by implication, estoppel or otherwise. No implied licenses are granted under this Agreement. Each Party hereby covenants and agrees not to use or sublicense any of its rights under the licenses set forth in this
Article 8 except as expressly permitted in this Agreement. 
  
 8.6 Exclusivity. During the Term, New River hereby covenants and agrees not to, itself or through or with any Affiliate or Third Party, (a) develop, market, promote, sell, or otherwise commercialize any pharmaceutical products
containing or comprising [*] or other compound where an active moiety of such compound is [*], other than Collaboration Products, (b) or develop, market, promote, sell, or otherwise commercialize any pharmaceutical products containing
[*] formulated for [*] for the treatment or prevention of ADHD, other than Collaboration Products, or (c) grant any license to a Third Party to perform any activities described in the preceding clauses (a) or (b), in each case without
the express prior written approval of Shire. 
  
 8.7
Nonassertion. New River and its Affiliates hereby covenant and agree not to, alone or in cooperation with any Third Party, [*], the manufacture, use, offer for sale, sale, distribution, import or export of which is done under and
in accordance with the terms of this Agreement. This covenant will run with and attach to any and all intellectual property owned or controlled, in whole or in part, by New River and shall be binding upon any assignee of any intellectual property
from New River. 
  
 8.8 [*]. New River will be
permitted to terminate this Agreement by written notice effective upon receipt if [*] (each such [*]). Shire will include provisions in all agreements granting sublicenses of Shire’s rights hereunder providing that if the
sublicensee or its Affiliates undertake a [*] with respect to [*] under which the sublicensee is sublicensed, Shire will be 

  

 - 30 - 

 
permitted to terminate such sublicense agreement. If a sublicensee of Shire (or an Affiliate of such sublicensee) undertakes a [*] [*] of any
such [*] under which such sublicensee is sublicensed, then Shire upon receipt of notice from New River of such [*] will terminate the applicable sublicense agreement. If Shire fails to so terminate such sublicense agreement, New River
may terminate Shire’s right to sublicense in the countr(ies) covered by such sublicense agreement and any sublicenses previously granted in such countr(ies) shall automatically terminate. In connection with such sublicense termination, Shire
shall cooperate with New River’s reasonable requests to cause such a terminated sublicensee to discontinue activities with respect to the Collaboration Product in such countr(ies). 
  
 ARTICLE 9 
 CONFIDENTIALITY 
  
 9.1 Confidential
Information. 
  
 9.1.1 Confidential
Information. As used in this Agreement, the term “Confidential Information” means all secret, confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer, electronic or other
form, provided pursuant to this Agreement or generated pursuant to this Agreement or the US Agreement by one Party or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving
Party”), including but not limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products, and any other materials that have not been made
available by the Disclosing Party to the general public. Notwithstanding the foregoing sentence, Confidential Information shall not include any information or materials that: 
  
 (a) were already known to the Receiving Party (other than under an obligation of confidentiality), at
the time of disclosure by the Disclosing Party, to the extent such Receiving Party has documentary evidence to that effect; 
  
 (b) were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the
Receiving Party; 
  
 (c) became generally
available to the public or otherwise part of the public domain after disclosure or development thereof, as the case may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this
Agreement; 
  
 (d) were disclosed to a
Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or 
  
 (e) were independently discovered or developed by or on behalf of the Receiving Party without the use
of the Confidential Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect. 
  
 9.1.2 Confidentiality Obligations. Each of New River and Shire shall keep all Confidential Information received from the
other Party with the same degree of care it maintains 

  

 - 31 - 

 
the confidentiality of its own Confidential Information. Neither Party shall use such Confidential Information for any purpose other than in performance of
this Agreement or disclose the same to any other Person other than to such of its and its Affiliates’ directors, managers, employees, independent contractors, agents or consultants who have a need to know such Confidential Information to
implement the terms of this Agreement or enforce its rights under this Agreement; provided, however, that a Receiving Party shall advise any of its and its Affiliates’ directors, managers, employees, independent contractors, agents or
consultants who receives such Confidential Information of the confidential nature thereof and of the obligations contained in this Agreement relating thereto, and the Receiving Party shall ensure (including, in the case of a Third Party, by means of
a written agreement with such Third Party having terms at least as protective as those contained in this Article 9) that all such directors, managers, employees, independent contractors, agents or consultants comply with such obligations as if they
had been a Party hereto. Upon termination of this Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the possession of the Receiving
Party or its directors, managers, employees, independent contractors, agents or consultants, except that the Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival
purposes. Such archival copy shall be deemed to be the property of the Disclosing Party, and shall continue to be subject to the provisions of this Article 9. It is understood that receipt of Confidential Information under this Agreement will not
limit the Receiving Party from assigning its employees to any particular job or task in any way it may choose, subject to the terms and conditions of this Agreement. 
  
 9.1.3 Permitted Disclosure and Use. Notwithstanding Section 9.1.2, a Party may disclose
Confidential Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) obtain Regulatory Approval of a Collaboration Product to the extent such disclosure is made to a Governmental Authority; (b)
comply with or enforce any of the provisions of this Agreement; (c) comply with Laws; or (d) comply with applicable stock exchange or Nasdaq regulation. If a Party deems it necessary to disclose Confidential Information of the other Party pursuant
to this Section 9.1.3, such Party shall give reasonable advance notice of such disclosure to the other Party to permit such other Party sufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such
information. In addition, notwithstanding Section 9.1.2, the Parties shall prepare standardized responses to anticipated inquiries from the public or press, stockholders, investors and/or analysts with respect to the Compound, Collaboration Product
or other activities hereunder that may be disclosed. Notwithstanding anything to the contrary in this Article 9, Shire shall not disclose to any Third Party Confidential Information of New River disclosing the Manufacture of Compound, without the
prior written consent of New River, not to be unreasonably withheld, delayed or conditioned. 
  
 9.1.4 Notification. The Receiving Party shall notify the Disclosing Party promptly upon discovery of any unauthorized use or
disclosure of the Disclosing Party’s Confidential Information, and will cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of such Confidential Information and to prevent
its further unauthorized use or disclosure. 
  

 - 32 - 

 9.2 Publicity; Filing of this Agreement. After the execution of the January Agreement, the
Parties announced the execution of the January Agreement using the form of the press release attached as Exhibit C (the “Joint Press Release”). Any other publication, news release or other public announcement relating to this
Agreement or to the performance hereunder, shall first be reviewed and approved by both Parties; provided, however, that any disclosure which is required by Law as advised by the disclosing Party’s counsel may be made without the prior consent
of the other Party. To the extent practicable, the disclosing Party shall be given at least three (3) Business Days advance notice of any such legally required disclosure, and the other Party shall provide any comments on the proposed disclosure
during such period. To the extent that either Party determines that it or the other Party is required to file or register this Agreement or a notification thereof to comply with the requirements of an applicable stock exchange or Nasdaq regulation
or any Governmental Authority, including without limitation the U.S. Securities and Exchange Commission, the Competition Directorate of the Commission of the European Communities or the U.S. Federal Trade Commission, such Party shall promptly inform
the other Party thereof. Prior to making any such filing, registration or notification, the Parties shall agree on the provisions of this Agreement for which the Parties shall seek confidential treatment, it being understood that if one Party
determines to seek confidential treatment for a provision for which the other Party does not, then the Parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The Parties shall
cooperate, each at its own expense, in such filing, registration or notification, including without limitation such confidential treatment request, and shall execute all documents reasonably required in connection therewith. In furtherance of the
foregoing, the Parties will agree as promptly as practicable after the Effective Date on the confidential treatment request to be filed with the U.S. Securities and Exchange Commission and the redacted form of this Agreement related thereto. In that
connection, any redaction reasonably requested by either Party shall be included in such filing. The Parties will reasonably cooperate in responding promptly to any comments received from the U.S. Securities and Exchange Commission with respect to
such filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a Party shall be relieved of such obligation to seek confidential treatment for a provision requested by the other Party if such treatment is
not achieved after the second round of responses to comments from the U.S. Securities and Exchange Commission. 
  
 9.3 Publication. Each Party shall submit copies of each proposed academic, scientific, medical and other publication or presentation that
contains or refers to the Licensed Patents, Licensed Know-How or otherwise relates to a Collaboration Product or any research or Development activities under this Agreement to the other Party at least sixty (60) days in advance of submitting such
proposed publication or presentation to a publisher or other Third Party. Such other Party shall have the right to review, comment on and approve each such proposed publication or presentation for accuracy and to ascertain whether such Party’s
Confidential Information is being inappropriately utilized and/or released. The non-publishing Party shall have the right to remove any of its Confidential Information prior to submission for publication or presentation. The publishing Party shall
redact or otherwise modify the proposed publication or presentation to remove any such Confidential Information of the other Party. In addition, in the event that the document includes data, information or material generated by a Party’s
scientists, and professional standards for authorship would be consistent with including such Party’s scientists as co-authors of the document, the names of such scientists will be included as co-authors. A Party may publicly disclose without
regard to the preceding 

  

 - 33 - 

 
requirements of this Section 9.3 any information that was previously disclosed in a public disclosure that was in compliance with such requirements.

  
 9.4 Use of Names. Neither Party shall use the
name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided,
however, that either Party may use the name of the other Party in any document filed with any regulatory agency or authority, including the FDA and the Securities and Exchange Commission. 
  
 9.5 Confidentiality of this Agreement. The terms of this Agreement shall be Confidential Information of each
Party and, as such, shall be subject to the provisions of this Article 9. 
  
 9.6 Disclosures Under Existing NDA. The Parties agree and acknowledge that New River and Shire US, Inc. entered into that certain Existing NDA. For purposes of this Section 9.6, the term “Existing
NDA” means that certain Non-Disclosure and Confidentiality Agreement, dated as of July 16, 2002, as amended by letter agreements on July 13, 2004, October 29, 2004, November 12, 2004, November 15, 2004, by and among the Parties and various
other Affiliates and independent contractors of Shire. The Parties agree that “Confidential Information” (as such term is used in the Existing NDA) disclosed to Shire Affiliates under the Existing NDA prior to the Effective Date shall be
deemed to have been disclosed under this Agreement and, from and after the Effective Date, shall be held in confidence by such Shire Affiliates in accordance with the terms of this Article 9. To the extent that Shire retains Prior Consultants to
perform activities under this Agreement in connection with which such Prior Consultant is provided Confidential Information of New River, then such Prior Consultant shall be made subject to the provisions of this Article 9 with respect to
disclosures of “Confidential Information,” as such term is used in the Existing NDA. The term “Prior Consultants” means those persons added as parties to the Existing NDA pursuant to those amendments to the Existing NDA
made as of November 12, 2004 and November 15, 2004. 
  
 9.7
Survival. The obligations and prohibitions contained in this Article 9 shall survive the expiration or termination of this Agreement for a period of ten (10) years. 
  
 ARTICLE 10 
 OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS 
  
 10.1 Ownership. 
  
 10.1.1
New River shall solely own, and it alone shall have the right to apply for Patents, within and outside of the United States for any New River Inventions and Shire shall solely own, and it alone shall have the right to apply for Patents, within
and outside of the United States for any Shire Inventions. New River and Shire will each own an undivided one-half interest in any Joint Inventions and any Patents claiming such Joint Inventions (“Joint Collaboration Patents”), in
each case without obligation to account to the other for the exploitation thereof or to seek consent of the other for the grant of any licenses thereunder, subject to the licenses and rights granted by the Parties in this Agreement. Each Party shall

  

 - 34 - 

 
promptly disclose to the other Party all Inventions made by it during the Term. The determination of inventorship for Inventions shall be made in accordance
with applicable Laws relating to inventorship set forth in the patent Laws of the United States (Title 35, United States Code). 
  
 10.1.2 Each Party will require all of its and its Affiliates’ employees to assign all Inventions that are the subject of
patent applications claiming Inventions that are developed, made or conceived by such employees according to the ownership principles described in this Section 10.1. Each Party will require any agents or independent contractors performing an
activity pursuant to this Agreement to assign all Inventions that are the subject of patent applications claiming Inventions that are developed, made or conceived by such agents or independent contractors to New River and/or Shire according to the
ownership principles described in this Section 10.1. 
  
 10.2
Disclosures; Disputes Regarding Inventions. Each Party shall, before filing a new patent application (including without limitation provisionals and continuations-in-part, but excluding continuations, divisionals, and requests for
continued examinations) claiming an Invention, promptly disclose such Invention to the other Party, including Joint Inventions, New River Inventions and Shire Inventions and shall provide the other Party with a copy of the proposed patent
application at least ten (10) Business Days before filing such application or such shorter time as may be required to preserve Patent rights, including, without limitation, the avoidance of a statutory bar. If the non-filing Party believes that the
filing Party’s proposed patent application discloses Confidential Information of the non-filing Party, the non-filing Party shall so notify the filing Party within such ten (10) Business Days, and the filing Party shall amend its proposed
application to comply with the confidentiality provisions of this Agreement. If the Parties are in agreement as to the designation of the Invention as Joint Invention, New River Invention or Shire Invention, they can continue as set forth in Section
10.3 below. If the Parties disagree as to whether an Invention is a Joint Invention, New River Invention or Shire Invention, and are unable to reach agreement within thirty (30) days after commencing discussions, then each Party will have the right
to avail itself of any legally recognizable remedy in accordance with Article 15 of this Agreement and applicable Law. 
  
 10.3 Patent Filings. 
  
 10.3.1 New River Responsibilities. New River shall prepare, file, prosecute and maintain Patents to cover (a) New River
Inventions (the “New River Collaboration Patents”), and (b) the Licensed Patents. New River shall keep Shire informed of the status of each such Patent and shall give Shire a reasonable opportunity to provide comments to any
communication from any patent office. New River shall give reasonable consideration to any suggestions or recommendations of Shire concerning the preparation, filing, prosecution and maintenance thereof, including suggestions of the JIPC pursuant to
the terms set forth in Sections 2.4 and 2.6.3. Promptly after the Effective Date, New River shall provide Shire with copies of the file histories of all Licensed Patents and shall update such file histories promptly upon receipt of any additional
communications from any patent offices and patent counsel or agents pertaining thereto. New River shall also provide Shire with copies of any communications from any patent offices and patent counsel or agents pertaining to any New River
Collaboration Patents. New River, at Shire’s request, shall [*] [*] in any New River Collaboration Patent, Licensed Patent or 

  

 - 35 - 

 
a continuation or divisional of either of the foregoing, the type of application being at New River’s discretion; provided, however, New River may
refuse to [*] if New River reasonably believes, in good faith, that [*] If the [*] New River will [*] and shall give reasonable consideration to any suggestions or recommendations of Shire concerning [*]. The
Parties shall cooperate reasonably in the prosecution of all Patents under this Section 10.3.1 and shall share all material information relating thereto promptly after receipt of such information. If, during the term of this Agreement, New River
intends to allow any Licensed Patent to expire or intends to otherwise abandon any Licensed Patent, New River shall notify Shire of such intention at least sixty (60) days prior to the date upon which such Licensed Patent shall expire or be
abandoned, and Shire shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof. 
  
 10.3.2 Shire Responsibilities. Shire shall file, prosecute and maintain Patents to cover Shire
Inventions conceived pursuant to this Agreement or the US Agreement (the “Shire Collaboration Patents”). Shire shall keep New River informed of the status of each such Patent and shall give reasonable consideration to any
suggestions or recommendations of New River concerning the preparation, filing, prosecution and maintenance thereof, including the suggestions of the JIPC pursuant to the terms set forth in Sections 2.4 and 2.6.3. The Parties shall cooperate
reasonably in the prosecution of all Shire Patents under this Section 10.3.2 and shall share all material information relating thereto promptly after receipt of such information. If, during the Term, Shire intends to allow any Shire Patent to which
New River has a license under this Agreement to expire or intends to otherwise abandon any Shire Patent, Shire shall notify New River of such intention at least sixty (60) days prior to the date upon which such Shire Patent shall expire or be
abandoned, and New River shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof. 
  
 10.3.3 Jointly Owned Patents. The responsibility for the filing, prosecution and maintenance
of Joint Collaboration Patents shall be determined by the Parties, including conducting related interference and opposition proceedings relating thereto, without prejudice to ownership, on behalf of both Parties based on a good faith determination
of the relative contributions of the Parties to the Invention and the relative level of interest of the Parties in the Invention; provided, however that the Parties may also decide not to file a Joint Collaboration Patent for any such Joint
Invention. At least ten (10) Business Days prior to the contemplated filing, the Party responsible for such activities for a Joint Collaboration Patent shall submit a substantially completed draft of such Joint Collaboration Patent to the other
Party for its approval. Should the agreed upon Party elect not to prepare and/or file any such Joint Collaboration Patent, it shall (a) provide the other Party with written notice as soon as reasonably possible after making such election but in any
event no later than twenty (20) Business Days before the other Party would be faced with a possible loss of rights, (b) give the other Party the right, at the other Party’s discretion, to prepare, file, prosecute or maintain the Joint
Collaboration Patent, and (c) offer reasonable assistance in connection with such preparation, filing, prosecution or maintenance. 
  
 10.3.4 Cooperation. The Parties agree to cooperate in the preparation, filing, prosecution and maintenance of all Patents
under this Section 10.3, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing 

  

 - 36 - 

 
relevant technical reports to the filing Party concerning the Invention disclosed in such Patent, obtaining execution of such other documents which shall be
needed in the filing and prosecution of such Patent, and, as requested, updating each other regarding the status of such Patent, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing all information and
data in its possession reasonably necessary to obtain or maintain such Patents. 
  
 10.3.5 Patent Expenses. Patent Expenses for the ROW Territory shall be borne [*]; provided, however, if New River
incurs any expenses for any country in which Shire has notified New River at least thirty (30) days advance notice in writing either that it does not intend to Commercialize a Collaboration Product in such country, or that it has abandoned such
Commercialization, any fee or expense incurred with respect to patents in such country shall be the sole responsibility of New River and shall not be deemed Patent Expenses effective as of the end of such notice period. Within five (5) Business Days
following the end of each calendar quarter, each Party shall deliver a report outlining its Patent Expenses for such quarter. Within thirty (30) days following the end of each such quarter, the Party incurring less than [*] of such expenses
during the quarter shall reimburse the other Party an amount sufficient to [*] each Party’s share of such costs. In the event that Shire notifies New River that it does intend to Commercialize a Collaboration Product in any country in
which it has previously notified of an intention not to Commercialize or abandoned Commercialization, or so Commercializes such Collaboration Product in such country, then Shire shall reimburse New River for an amount equal to [*] of the
Patent Expense for the applicable country incurred from the effective date of such notification. 
  
 10.4 Third-Party Patent Rights. Except as otherwise provided in Section 11.1 below, neither Party makes any warranty with respect to the
validity, perfection or dominance of any Patent or other proprietary right or with respect to the absence of rights in Third Parties which may be infringed by the Manufacture or Commercialization of any Collaboration Product. Each Party agrees to
bring to the attention of the other Party any patent or patent application it discovers, or has discovered, and which relates to the subject matter of this Agreement. 
  
 10.5 Enforcement and Defense of Patents. 
  
 10.5.1 Infringement of Third Party Patents. 
  
 (a) Third Party Claims; Third Party Royalties.
In the event of a Third Party Claim against Shire, New River or their respective Affiliates alleging that the making, using, importing, selling or offering to sell a Collaboration Product infringes or will infringe claims in any patents of a Third
Party, the Party first obtaining knowledge of such Third Party Claim shall immediately provide the other Party notice of such Third Party Claim with the related facts in reasonable detail. Shire shall have the first right, but not the obligation, to
control such defense with respect to the Collaboration Product with an attorney of Shire’s choice if Shire or any of its Affiliates are named as a party to such Third Party claim and New River or any of its Affiliates are not. In such case, New
River shall have the right to be represented by independent counsel at New River’s own expense. New River shall have the first right, but not the obligation, to control such defense with respect to the Collaboration Product with an attorney of
New River’s choice if New River or any of its Affiliates are named as a party to such Third Party claim and Shire or any of its Affiliates are not. In such case, Shire shall have the right to 

  

 - 37 - 

 
be represented by independent counsel at Shire’s own expense. If either Party refuses to accept control of the defense of a Third Party Claim for which
it has the first right to control defense hereunder within [*] after receiving or giving notice thereof, then the other Party shall have the right to defend against such Third Party Claim. In such case, such refusing Party shall have the
right to be represented by independent counsel at its own expense. If (1) Shire or any of its Affiliates and (2) New River or any of its Affiliates are named as parties to such Third Party Claim, then the Parties will have the joint right, but not
the obligation, to control such defense with respect to the Collaboration Product with an attorney of their mutual agreement. If the Parties are unable to agree on such joint defense, then the Parties will use good faith efforts to determine the
Party to assume control of such defense and choice of counsel. In such case, the other Party shall have the right to be represented by independent counsel at its own expense. If, as a result of a judgment in any litigation or settlement with a Third
Party, Shire or its Affiliates are required to pay royalties to any Third Party (“Third Party Royalty”), then, on a country-by-country basis and product-by-product basis, the royalty due to New River under this Agreement with
respect to Net Sales in the ROW Territory will be [*] of the Third Party Royalty, provided that the royalty due to New River will not be reduced to less than [*] of the royalty that would be due to New River in the absence of such
Third Party Royalty. 
  
 (b)
Cooperation. If a Party shall become engaged in or participate in any suit described in this Section 10.5.1, the other Party shall cooperate, and shall cause its and its Affiliates’ employees to cooperate, with such Party in all
reasonable respects in connection therewith, including giving testimony and producing documents lawfully requested, and using its reasonable and diligent efforts to make available to the other, at no cost to the other (other than reimbursement of
actually incurred, reasonable out-of-pocket travel and lodging expenses), such employees who may be helpful with respect to such suit, investigation, claim, interference or other proceeding. 
  
 10.5.2 Prosecution of Infringers. 

 
 (a) Notice. If either Party learns that a
Third Party is infringing or allegedly infringing any Patent within the Licensed Patents, the Shire Patents or the Joint Collaboration Patents or if any Third Party claims that any such Patent is invalid or unenforceable, it will promptly notify the
other Party thereof including available evidence of infringement or the claim of invalidity or unenforceability. The Parties will cooperate and use reasonable efforts to stop such alleged infringement or to address such claim without litigation.

  
 (b) Enforcement and Defense of Licensed
Patents, Joint Collaboration Patents and Shire Collaboration Patents. 
  
 (i) Shire will have the first right (but not the obligation) to take the appropriate steps to enforce or defend any Patent within the Shire Collaboration Patents. Shire may take steps including the initiation,
prosecution and control any suit, proceeding or other legal action by counsel of its own choice. Each of New River and Shire will bear the costs of such enforcement or defense [*]. Notwithstanding the foregoing, New River will have the right,
at its own expense, to be represented in any such action by counsel of its own choice. 
  

 - 38 - 

 (ii) If, pursuant to Section 10.5.2(b)(i), Shire fails to take the appropriate
steps to enforce or defend any Patent within the Shire Collaboration Patents within [*] days of the date one Party has provided notice to the other Party pursuant to Section 10.5.2(a) of such infringement or claim, then New River will have
the right (but not the obligation), at its own expense, to bring any such suit, action or proceeding by counsel of its own choice and Shire will have the right, at its own expense, to be represented in any such action by counsel of its own choice.

  
 (iii) New River will have the first
right (but not the obligation) to take the appropriate steps to enforce or defend any Patent within the Licensed Patents. New River may, in any such instance, take steps including the initiation, prosecution and control any suit, proceeding or other
legal action by counsel of its own choice. Each of New River and Shire will bear the costs of such enforcement or defense [*]. Notwithstanding the foregoing, Shire will have the right, at its own expense, to be represented in any such action
by counsel of its own choice. 
  
 (iv)
If, pursuant to Section 10.5.2(b)(iii), New River fails to take the appropriate steps to enforce or defend any Patent within the Licensed Patents within [*] of the date one Party has provided notice to the other Party pursuant to Section
10.5.2(a) of such infringement or claim, then Shire will have the right (but not the obligation), at its own expense, to bring any such suit, action or proceeding by counsel of its own choice, and New River will have the right, at its own expense,
to be represented in any such action by counsel of its own choice. 
  
 (v) In the case of Joint Collaboration Patents, the Parties will decide whether Shire or New River will have the first right (but not the obligation) to take the appropriate steps to enforce or defend any
Patent within the Joint Collaboration Patents. The Party so selected may, in any such instance, take steps including the initiation, prosecution and control any suit, proceeding or other legal action by counsel of its own choice. Each of New River
and Shire will bear the costs of such enforcement or defense [*] and the Party that is not so selected will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 
  
 (vi) If, pursuant to Section 10.5.2(b)(v), the Party
selected fails to take the appropriate steps to enforce or defend any Patent within the Joint Collaboration Patents within [*] of the date one Party has provided notice to the other Party pursuant to Section 10.5.2(a) of such infringement or
claim, then the other Party will have the right (but not the obligation), at its own expense, to bring any such suit, action or proceeding by counsel of its own choice, and the Party so selected will have the right, at its own expense, to be
represented in any such action by counsel of its own choice. 
  
 (vii) Notwithstanding Sections 10.5.2(b)(i)-(vi), Shire will have the sole discretion whether to commence [*] and the sole right to commence [*] which may result in [*] [*] for such
Third Party. For the avoidance of doubt, New River shall not have the right to commence [*] [*] which may result [*] for such Third Party. Any such [*] as may be required by Law. 
  

 - 39 - 

 (c) Cooperation; Damages. 
  
 (i) If one Party brings any suit, action or
proceeding under this Section 10.5.2, the other Party agrees to be joined as party plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or
proceeding; provided, however, that neither Party will be required to transfer any right, title or interest in or to any property to the other Party or any other party to confer standing on a Party hereunder. 
  
 (ii) The Party not pursuing the suit, action or
proceeding hereunder will provide reasonable assistance to the other Party, including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any
out-of-pocket expenses incurred by the non-enforcing or defending Party in providing such assistance. 
  
 (iii) Neither Party will settle or otherwise compromise any such suit, action or proceeding in a way that adversely affects the
other Party’s intellectual property rights or its rights or interests with respect to the Collaboration Product without such Party’s prior written consent. 
  
 (iv) Any settlements, damages or other monetary awards (the “Recovery”) recovered
pursuant to a suit, action or proceeding brought pursuant to Section 10.5.2 will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining
amounts (if any) with respect to a country in the ROW Territory to be shared [*]. 
  
 10.6 Notice of Certification. New River and Shire each shall immediately give notice to the other of any certification filed under the U.S. Drug Price Competition and Patent Term Restoration Act of 1984
(or its foreign equivalent) claiming that a Licensed Patent, Joint Collaboration Patent or a Shire Collaboration Patent is invalid or that infringement of a Licensed Patent, Joint Collaboration Patent or Shire Collaboration Patent will not arise
from the manufacture, use, offer for sale, sale or importation product by a Third Party (“Hatch-Waxman Certification”). Nothing in this Section 10.6 shall prevent or otherwise limit New River’s right to take any and all such
actions with regard to the matters described in this Section 10.6 as required by applicable Law. 
  
 10.7 Patent Term Extensions. New River and Shire shall cooperate in good faith in gaining patent term extensions due to delay(s) in
Regulatory Approval wherever applicable to the Licensed Patents, Joint Collaboration Patents and Shire Collaboration Patents. However, Shire shall have the sole discretion in determining which Licensed Patent(s), Joint Collaboration Patent(s), or
Shire Collaboration Patent(s) to extend for any particular compound, composition, article, product, process, or use. 
  
 10.8 Listing of Patents. Shire shall have the right to determine which of the [*], if any, shall be submitted for inclusion in the
Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country. Shire shall notify New River at 

  

 - 40 - 

 
least ten (10) Business Days prior to the deadline for any such submission, and New River shall submit the designated Patents in accordance with applicable
Law. In addition, New River may in its discretion, and to the extent permitted by Law, submit any additional [*] that are not designated by Shire. Nothing in this Section 10.8 shall prevent or otherwise limit New River’s right to take
any and all such actions with regard to the matters described in this Section 10.8 as required by applicable Law. 
  
 10.9 Trademarks and Copyrights. 
  
 10.9.1 Product Trademarks. All Collaboration Products shall be marketed and sold worldwide under and in connection with
trademarks, trade dress, logos and slogans selected in accordance with this Section 10.9. 
  
 10.9.2 Trademark Selection. Shire shall select trademarks, trade dress, logos and slogans for a Collaboration Product for
use in the ROW Territory. Trademark(s), trade dress, logo(s) and slogan(s) under which Collaboration Products are marketed or sold (other than either Party’s corporate trademarks or trade names, and New River’s CarrierwaveTM mark used in connection with technology related to the Compound) shall be used only pursuant to the terms of this Agreement to
identify and in connection with the marketing of Collaboration Products, and shall not be used by either Party to identify or in connection with the marketing of any other products. Each Party shall have a right to prior review and approval of all
Promotional Materials incorporating any of its trademarks, trade dress, logos or slogans sufficient to permit such Party to maintain quality control over its trademarks, trade dress, logos and slogans. All trademarks shall be registered by the Party
owning such trademark in its name as owner in all applicable countries. All trade dress, logos, slogans and designs may be registered by the Party owning such trade dress, logos or slogan, in the discretion of such Party, in its name as owner in all
applicable countries. 
  
 10.9.3
Ownership of Trademarks. New River will continue to own, throughout the world, any trademarks, trade dress, logos and/or slogans, and all registrations therefor, used or intended to be used for a Collaboration Product which New River owns
as of the Effective Date (the “New River Marks”). Shire will own, throughout the world, all other trademarks, trade dress, logos and/or slogans, and all registrations therefor, used or intended to be used for a Collaboration Product
(the “Shire Marks”). All goodwill attributable to a New River Mark generated by the Commercialization of a Collaboration Product bearing a New River Mark shall inure to the benefit of New River. All goodwill attributable to a Shire
Mark generated by the Commercialization of a Collaboration Product bearing a Shire Mark shall inure to the benefit of Shire. If Shire determines to use a New River Mark for the Commercialization of a Collaboration Product in the ROW Territory, New
River shall grant to Shire, a non-exclusive, royalty-free license, with the right to grant sublicenses in accordance with Section 8.3, to use such New River Mark in the ROW Territory, solely in conjunction with the Commercialization of the
Collaboration Products. Shire shall comply with New River’s then-current guidelines for trademark usage, a copy of which shall be provided to Shire from time to time, in connection with Shire’s use of such New River Mark. New River shall
solely bear all costs of prosecution of applications to register and to record licenses (if applicable) for, and maintenance of, each New River Mark for each Collaboration Product. Shire shall solely bear all costs of prosecution 

  

 - 41 - 

 
of applications to register and to record licenses (if applicable) for, and maintenance of, each Shire Mark for each Collaboration Product. 
  
 10.9.4 Infringement of Trademarks and
Copyrights. Each Party shall take all reasonable and appropriate steps to protect, defend and maintain each trademark and copyright owned by such Party hereunder for use in connection with a Collaboration Product, and all registrations therefor.
Each Party shall notify the other Party promptly upon learning of any actual, alleged or threatened infringement of a trademark, trade dress, logo, slogan, copyright, or of any unfair trade practices, trade dress imitation, passing off of
counterfeit goods, or like offenses. Upon learning of such offenses, the Party owning such trademark or copyright shall have the obligation to, in consultation with the other Party, institute and control an appropriate action or proceeding to halt
the offense, unless the Parties otherwise mutually agree. All Recoveries in connection therewith will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party,
with any remaining amounts (if any) with respect to a country in the ROW Territory to be shared equally. Such other Party shall have the right to participate fully in all such actions or proceedings. During the Term, in the event that the Party
owning such trademark or copyright does not undertake such an infringement action then, in the case that such owning Party is New River, Shire shall be permitted to do so and all Recoveries in connection therewith will be allocated first to the
costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) with respect to a country in the ROW Territory to be shared equally. For the purposes of this
Section 10.9.4, the Party that brings suit to enforce a given trademark or copyright shall also have the right to control settlement of such claim; provided, however, that no settlement shall be entered into without the written consent of the other
Party, not to be unreasonably withheld, conditioned or delayed. 
  
 10.9.5 Costs of Defense. All of the unrecovered costs, expenses and legal fees (including internal costs, expenses and legal fees) incurred by the Parties in bringing, maintaining and prosecuting any
action to maintain, protect or defend a trademark (or registration therefor) or copyright (or registration therefor) covering or used or intended to be used in connection with the marketing or sale of a Collaboration Product in the ROW Territory
will be [*]. 
  
 10.9.6
Acknowledgment of Ownership. Each Party acknowledges the sole ownership by the other Party and validity of all trademarks, trade dress, logos and slogans owned by the other Party and used or intended to be used on or in connection with
the marketing or sale of a Collaboration Product. Each Party agrees that it will not at any time during or after the Term assert or claim any interest in or do anything which may adversely affect the validity or enforceability of any trademark,
trade dress, logo or slogan owned by the other Party and used or intended to be used on or in connection with the marketing or sale of a Collaboration Product. Neither Party will register, seek to register or cause to be registered any trademarks,
trade dress, logos or slogans owned by the other Party and used or intended to be used on or in connection with the marketing or sale of a Collaboration Product or any variation thereof, under any law providing for registration of trademarks,
service marks, trade names, fictitious names or similar laws, as an Internet domain name, or in the name of a corporation, partnership, limited liability company or other entity, without the other Party’s prior written consent, and neither
Party will register, seek to register or cause to be registered any copyright, nor register or patent, seek to 

  

 - 42 - 

 
register or patent or caused to be registered or patented, of the other Party, without the other Party’s prior written consent. 
  
 ARTICLE 11 
 REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY 
  
 11.1 Representations, Warranties and Covenants. 
  
 11.1.1 Each of the Parties hereby represents and warrants to the other Party that, as of the Effective Date: 
  
 (a) Such Party has full corporate right, power and
authority to enter into this Agreement and to perform its respective obligations under this Agreement and that it has the right to grant the licenses and sublicenses granted pursuant to this Agreement. 
  
 (b) This Agreement is a legal and valid obligation
binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party
or by which it is bound, nor violate any Law of any Governmental Authority having jurisdiction over it. 
  
 (c) Such Party has not granted any right to any Third Party that would conflict with the rights granted to the other Party
hereunder. 
  
 (d) Except for Regulatory
Approvals, pricing and/or reimbursement approvals, manufacturing approvals and/or similar approvals necessary for the Development, Manufacture or Commercialization of the Compound and Collaboration Products, such Party has obtained all necessary
consents, approvals and authorizations of all Government Authorities and other Persons required to be obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement; provided, that, for clarity,
it is agreed that a termination by a Party in accordance with Section 12.6 shall not be deemed to constitute evidence of a breach of this Section 11.1.1(d). 
  
 11.1.2 Each Party hereby covenants to the other Party that, during the Term: 
  
 (a) Such Party will not grant any right to any Third
Party that would conflict with the rights granted to the other Party hereunder; 
  
 (b) In the course of the Development of the Compound and Collaboration Products, such Party will not use any employee or consultant
that is debarred by the FDA (or any foreign equivalent) or, to such Party’s knowledge, is the subject of debarment proceedings by the FDA (or any foreign equivalent). 
  
 11.1.3 New River hereby represents and warrants to Shire that, as of the Effective Date: 

 
 (a) There is no action or proceeding pending or,
to New River’s knowledge, threatened, with respect to Collaboration Products and/or the Compound, including 

  

 - 43 - 

 
without limitation the conduct of any clinical trials, manufacturing activities or other activities, or that questions the validity of this Agreement or any
action taken by New River in connection with the execution of this Agreement. There are no material unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or
by an arbitrator) against New River with respect to Collaboration Products and/or the Compound, including without limitation the conduct of any clinical trials, manufacturing activities or other activities. 
  
 (b) IND #67482 and IND #70109 (i) have been filed in
the name of New River and are in effect; and (ii) to New River’s knowledge, constitutes all governmental approvals, permits and licenses required by New River in connection with the performance of clinical trials concerning the Collaboration
Product or the Compound, as such clinical trials are conducted by New River. Attached hereto as Schedule 11.1.3(b) is a true, correct and complete list of all INDs and Drug Approval Applications filed with a Governmental Authority relating to
the Compound or a Collaboration Product. 
  
 (c) Intellectual Property. 
  
 (i) Schedule 11.1.3(c)(i)(I) sets forth a true and complete list of all Licensed Patents that [*]. Schedule 11.1.3(c)(i)(II) sets forth a true and complete list of all Patents that [*]. Such schedules
contain, where relevant, all application numbers and filing dates, registration numbers and dates, jurisdiction, next action date with description for action to be taken, and notice of whether fees of any kind are yet to be paid. 
  
 (ii) New River has submitted all information related
to the Compound, Collaboration Product and/or Licensed Patents to the United States Patent and Trademark Office required to be submitted in accordance with 37 C.F.R. 1.56, 1.97 and 1.98. 
  
 (iii) The Licensed Patents and Licensed Know-How constitute all intellectual property Controlled by
New River that is necessary or useful to Manufacture, Develop, use or Commercialize the Compound and/or Collaboration Product for ADHD, and to the knowledge of New River there is not any other intellectual property necessary for such purposes that
is not Controlled by New River. 
  
 (iv)
Neither New River nor any of its Affiliates has received any written notice from any Third Party challenging or questioning the right of New River to use or license any of the Licensed Know-How or Licensed Patents. 
  
 (v) Each of New River and its Affiliates owns all
right, title and interest in and to, or has a license, sublicense or otherwise permission to use and license, all of the Licensed Know-How or Licensed Patents free and clear of all encumbrances and no person other than New River (including any
current or former employee or consultant of New River) has any proprietary, commercial or other interest in any of the Licensed Know-How or Licensed Patents. There are no existing agreements, options, commitments, or rights with, of or to any person
to acquire or obtain any rights to, any of the Licensed Know-How or Licensed Patents. 
  

 - 44 - 

 (vi) The use or practice of the Licensed Know-How and Licensed Patents as it has
been and is now being conducted do not, to the knowledge of New River, infringe or misappropriate the intellectual property rights of a Third Party. Neither New River nor any of its Affiliates has received any written notice from any person, or has
knowledge of, any actual or threatened claim or assertion that the use or practice of the Licensed Patents or Licensed Know-How infringes or misappropriates the intellectual property rights of a Third Party. 
  
 (vii) New River has the right to grant to Shire the
licenses set forth in this Agreement under the Licensed Know-How or Licensed Patents, free of any rights or claims of any Third Party and without payment of any royalties, license fees or other amounts to any Third Party. 
  
 (viii) All Patents within the Licensed Patents are
in full force and effect, valid, subsisting and, in the case of issued Patents, enforceable, and inventorship of the Licensed Patents is properly identified on such Licensed Patents. None of the Licensed Patents is currently involved in any
interference, reissue, reexamination, or opposition proceeding, and neither New River nor any of its Affiliates has received any written notice from any person, or has knowledge, of such actual or threatened proceeding. 
  
 (ix) To New River’s knowledge, there is [*] of
any of the Licensed Know-How or Licensed Patents by [*]. 
  
 (x) There are no actions or proceedings (including any inventorship challenges) pending or, to the knowledge of New River, threatened with respect to any of the Licensed Know-How, Licensed Patents, Compound or
Collaboration Products nor have any such actions or proceedings been brought or, to the knowledge of New River, threatened during the past six (6) years, in each case which have not been resolved without impairment of New River’s rights in and
to any of the Licensed Know-How, Licensed Patents, Compound or Collaboration Products and without the obligation to pay any royalties or other amounts to any Third Party with respect to the use of such technology or the sale of such products.

  
 (xi) Neither New River nor any of its
Affiliates has entered into any contract (A) granting any Third Party the right to bring infringement actions with respect to, or otherwise to enforce rights with respect to, any of the Licensed Know-How or Licensed Patents, or (B) expressly
agreeing to indemnify any Third Party against any charge of infringement of any of the Licensed Know-How or Licensed Patents. 
  
 (xii) Neither New River nor any of its Affiliates has entered into any contract granting any Third Party the right to control the
prosecution of any of the Patents in the Licensed Patents. 
  
 (xiii) All current and former employees and consultants of New River and its Affiliates who are or have been substantively involved in the design, review, evaluation or development of the Licensed Know-How or
Licensed Patents have executed 

  

 - 45 - 

 
written contracts or are otherwise obligated to protect the confidential status and value thereof and to vest in New River or its Affiliates exclusive
ownership of the Licensed Know-How or Licensed Patents. 
  
 (xiv) New River has made available to or provided Shire with copies of all material information and, as requested in writing by Shire, with copies of all books, records and data, in each case with respect to
Collaboration Products and/or the Compound. 
  
 (xv) All official fees, maintenance fees and annuities for the Licensed Patents have been paid through the Effective Date. 
  
 (xvi) Schedule 11.1.3(c)(i)(I) and Schedule 11.1.3(c)(i)(II) set forth a true and complete list of all registration,
application, maintenance, user, or renewal fees due within one hundred eighty (180) days after the Effective Date in connection with the Licensed Know-How or Licensed Patents. Any necessary registration, application, maintenance, user or renewal
fees due on or prior to the Effective Date in connection with the Licensed Know-How or Licensed Patents have been paid in a timely manner. All applicable government requirements that must be met on or prior to the Effective Date in connection with
the Licensed Know-How or Licensed Patents have been met in a timely manner with the relevant Governmental Authority. 
  
 (d) Compliance with Law. 
  
 (i) New River and its Affiliates and any outsourcing company and contract research organization to which New River or its
Affiliates have subcontracted activities in connection with Compound and Collaboration Products (the “Contractors”) have complied with all applicable Laws, permits, governmental licenses, registrations, approvals, concessions,
franchises, authorizations, orders, injunctions and decrees, including the Act, in the research, Development, Manufacture and use of the Collaboration Product for ADHD and Compound, and neither New River nor any of its Affiliates or, to the
knowledge of New River, its Contractors, has received any written notice from any Governmental Authority claiming that any such activities as conducted by them are not in such compliance. 
  
 (ii) Since January 1, 2002, no Governmental
Authority has served notice on New River or any of its Affiliates that the Licensed Know-How or Licensed Patents were or are in violation of any Law or the subject of any investigation. 
  
 (iii) Since January 1, 2002, none of New River or any of its Affiliates have received written notice
from any Governmental Authority that there are any circumstances currently existing that might reasonably be expected to lead to any loss or refusal to renew any material governmental licenses, permits, registrations, concessions, franchises and
authorizations relating to the Collaboration Product for ADHD, Compound or any of the Licensed Know-How or Licensed Patents. 
  
 (iv) New River and its Affiliates have complied in all material respects with all applicable Laws in connection with the
preparation and submission to the FDA of IND #67482 and #70109, and such INDs are in effect and good standing. IND #67482 and #70109 are the only INDs that New River or any of its Affiliates has filed with any 

  

 - 46 - 

 
Governmental Authority with respect to the Compound or a Collaboration Product. New River and its Affiliates have filed with the applicable regulatory
authority all required notices, supplemental applications and annual or other reports, including adverse experience reports, with respect to such INDs. No Drug Approval Application has been filed with any Governmental Authority with respect to the
Compound or a Collaboration Product. 
  
 (v)
No Governmental Authority has commenced or, to New River’s knowledge, threatened to initiate any action to reject or withdraw IND #67482 or #70109, or commenced or, to New River’s knowledge, threatened to initiate any action to enjoin
production of the Compound or Collaboration Product at any facility, nor has New River or any of its Affiliates or, to the knowledge of New River, any of its Contractors, received any notice to such effect since January 1, 2002. 
  
 (vi) All manufacturing operations conducted by New
River and its Affiliates and Contractors since January 1, 2002 relating to the manufacturing of the Collaboration Product for ADHD and/or Compound have been conducted in compliance with all Laws, including without limitation all cGMPs. 

 
 (vii) All Development activities conducted by New
River and its Affiliates and Contractors since January 1, 2002 relating to the Collaboration Product for ADHD and/or Compound have been conducted in compliance with all Laws, including without limitation all cGCPs and cGLPs. 
  
 (viii) New River has delivered or otherwise made
available to Shire copies of all substantive or material (A) reports of FDA Form 483 inspection observations, (B) establishment inspection reports, (C) warning letters, and (D) other documents that assert ongoing lack of compliance in any material
respect with any applicable laws (including those of the FDA), in each case to the extent received by New River or any of its Affiliates or, to the knowledge of New River, any of its Contractors from the FDA relating to a Collaboration Product
and/or Compound. Neither New River nor any of its Affiliates has received any such reports, letters or other documents from any other Governmental Authority relating to a Collaboration Product and/or Compound. 
  
 (ix) To New River’s knowledge, no employee or
agent of New River or any of its Affiliates or Contractors has made an untrue statement of a material fact to any Governmental Authority with respect to the Collaboration Product for ADHD and/or Compound (whether in any submission to such
Governmental Authority or otherwise), or failed to disclose a material fact required to be disclosed to any Governmental Authority with respect to the Collaboration Product and/or Compound. 
  
 (x) In the course of the Development of the Compound
and Collaboration Products, New River has not used any employee or consultant that is debarred by the FDA or, to New River’s knowledge, is the subject of debarment proceedings by the FDA. 
  
 (xi) Representatives of New River and its Affiliates
have disclosed to Shire any facts reasonably believed in good faith to be material regarding: (A) preclinical and clinical study results and protocols for the Collaboration Product for ADHD 

  

 - 47 - 

 
and/or Compound; (B) any communications to or from any Governmental Authority with respect to the Collaboration Product for ADHD and/or Compound, including
IND submissions, any Governmental Authority minutes of meetings and telephone conferences; (C) any Governmental Authority requests for data and studies on the Collaboration Product for ADHD and/or Compound; and (D) adverse drug experiences and other
IND safety reports with respect to the Collaboration Product for ADHD and/or Compound. 
  
 (xii) New River and its Affiliates do not have any knowledge of any preliminary or other results from any clinical trials relating
to the lack of efficacy of the Compound or Collaboration Product in human beings. 
  
 For purposes of the foregoing sections, “New River” and “its Affiliates” shall in all cases include [*] 
  
 11.2 Limitation on Representations or Warranties. Notwithstanding anything to the contrary herein, neither Party will be in breach of any
representation or warranty made pursuant to this Article 11 to the extent that the Party alleged to have so breached can demonstrate that the Party alleging such breach had, on or prior to the Effective Date, actual knowledge of such breach of such
representation or warranty. 
  
 11.3 Performance by
Affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party shall remain responsible for and be guarantor of the performance by its Affiliates
and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against an
Affiliate or subcontractor, for any obligation or performance hereunder prior to proceeding directly against such Party. Wherever in this Agreement the Parties delegate responsibility to Affiliates or local operating entities, the Parties agree that
such entities may not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 
  
 11.4 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 11.1 OF THIS AGREEMENT, NEW RIVER AND SHIRE MAKE NO
REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND NEW RIVER AND SHIRE EACH SPECIFICALLY DISCLAIMS ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL,
EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES. 
  
 11.5 Limitation of Liability. IN NO
EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND 

  

 - 48 - 

 
ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT LIMIT EITHER PARTY’S OBLIGATIONS TO THE OTHER PARTY UNDER ARTICLE 9 AND
ARTICLE 14. 
  
 11.6 Essential Basis. The Parties
acknowledge and agree that the disclaimers, exclusions and limitations of liability set forth in this Article 11 form an essential basis of this Agreement, and that, absent any of such disclaimers, exclusions or limitations of liability, the terms
of this Agreement, including, without limitation, the economic terms, would be substantially different. 
  
 ARTICLE 12 
 TERM AND TERMINATION 
  
 12.1 Term. This Agreement shall commence as of the Effective
Date and, unless sooner terminated as provided herein, shall expire on a country-by-country basis upon expiration of all royalty obligations in such country for all Collaboration Products, pursuant to Section 6.3.4 (the “Term”).

  
 12.2 Breaches (General). 
  
 12.2.1 If either Party (the “Breaching
Party”) shall have committed a breach of this Agreement, the other Party (the “Notifying Party”) shall provide written notice of such breach to the Breaching Party. For all allegations of breach other than an allegation of
Material Breach (as defined below), the Parties hereby agree that they shall seek to resolve the matter during the notice and cure period provided in Section 12.2.2 and may thereafter commence litigation pursuant to Article 15. 
  
 12.2.2 Upon receipt of a notice of breach other than
a Material Breach, the alleged Breaching Party shall have [*] within which to cure such breach following receipt of such notice [*] in the event of non-payment unless such payment obligation is being disputed in good faith). If the
matter is not resolved to the satisfaction of the Notifying Party during such cure period, then either Party may invoke the provisions of Article 15 with respect to claims for damages and other requests for equitable relief, but neither Party shall
have any right to terminate this Agreement for such breach. 
  
 12.2.3 The Parties may resort to the dispute resolution mechanisms of Article 15, and may seek all remedies in law or equity other than termination of this Agreement, without invoking the mechanisms of Section
12.3. 
  
 12.3 Allegations of Material Breach. 

 
 12.3.1 The Parties intend that this Agreement
shall survive breach, and shall not be terminable in the event of breach, unless the breach is [*] under this Agreement [*] to such an extent that [*] for the [*] interests taken as a whole under [*], considered in
the aggregate as a single transaction and as if set forth in a single agreement (“Material Breach”). The Parties acknowledge and agree that, so long as such breach satisfies the standard for Material Breach described in this Section
12.3.1, a Material Breach may result from a breach of this Agreement only (irrespective of whether any breach, material or otherwise, has occurred with respect to the 

  

 - 49 - 

 
US Agreement), the US Agreement only (irrespective of whether any breach, material or otherwise, has occurred with respect to this Agreement), or both
agreements. In the event there is a dispute as to whether a Material Breach has occurred, this Agreement and the US Agreement shall survive pending a determination pursuant to Article 15 that a Material Breach has occurred. This Section 12.3 shall
apply to any allegation of Material Breach, with consequences as set forth herein. 
  
 12.3.2 If a Party believes that a Material Breach has occurred, it shall give written notice to the Breaching Party of the nature
of the breach and the reason the Notifying Party believes it is a Material Breach. The alleged Breaching Party shall then have a period of [*] [*] following receipt of such notice [*] in the event of non-payment unless such
payment obligation is being disputed in good faith) in which to cure the breach; provided, however, that if the Material Breach is other than the payment of money and is capable of being cured but cannot be reasonably cured in such [*]
period, then the right to terminate this Agreement shall not arise if the allegedly Breaching Party has (a) during such period of time submitted a plan that, if successfully carried out, would be effective in curing such Material Breach, and has
commenced its execution of such plan, and (b) diligently pursues such plan thereafter for a period of up to an additional [*]. Any such notice of alleged Material Breach by the Notifying Party shall include a reasonably detailed description
of all relevant facts and circumstances demonstrating, supporting and/or relating to each such alleged Material Breach by the Breaching Party. 
  
 12.3.3 If the alleged Material Breach is not cured within the cure period specified in Section 12.3.2, the Notifying Party may give
notice of termination (“Notice of Termination For Material Breach”). If the Breaching Party agrees that a Material Breach has occurred, then the Parties shall proceed to terminate this Agreement and the US Agreement in accordance
with Section 12.3.5 and Article 13 of this Agreement and Section 13.3.5 and Article 14 of the US Agreement. If the Breaching Party does not agree that a Material Breach has occurred, then this Agreement and the US Agreement shall survive, and the
Parties shall continue to perform their obligations hereunder, until the issue of whether there has been a Material Breach by the Breaching Party is resolved in accordance with Article 15. 
  
 12.3.4 If the Notifying Party gives Notice of
Termination For Material Breach, and it is later determined by a court pursuant to Article 15 that in fact there has not been a Material Breach by the Breaching Party, then this Agreement and the US Agreement shall continue in full force and effect.

  
 12.3.5 If the Notifying Party gives
Notice of Termination For Material Breach and this Agreement and the US Agreement terminate, either because such notice is accepted by the Breaching Party or it is determined by a court pursuant to Article 15 that there has been a Material Breach by
the Breaching Party, then the Notifying Party shall, within [*] after such determination, deliver written notice (the “Purchase Notice”) to the Breaching Party of the purchase by the Notifying Party of the Purchase Interest
(as such term is defined below). 
  
 (a)
The price (the “Purchase Price”) to be paid to purchase the entire interests, rights and obligations of the Breaching Party and/or its Affiliates under this Agreement and the US Agreement (the “Purchase
Interest”) shall be [*] [*], it being understood and agreed that [*] shall be applied [*] and that all intellectual property rights and other assets licensed or 

  

 - 50 - 

 
otherwise made available by the Parties and their respective Affiliates under this Agreement and the US Agreement shall be [*]. 
  
 (b) Each Party shall, within [*] after the
delivery of the Purchase Notice, retain an internationally recognized investment banking firm to determine the Purchase Price. Each such investment banking firm shall set forth such determination in a written report and, on a mutually agreeable date
no later than [*] after the delivery of the Purchase Notice, submit such report to the other Party. 
  
 (c) The Purchase Price shall be the amount equal to [*] However, if [*], a third internationally recognized
investment banking firm (which is independent of both Parties) shall determine such fair market value by [*]. Such third investment banking firm shall be selected by the first two investment banking firms; provided, however, that, if the two
investment banking firms are unable to select a third investment banking firm within twenty (20) days following determination that [*], then each of the two initial investment banking firms shall within twenty (20) days thereafter submit the
names of three internationally recognized investment banking firms (which are independent of both Parties) willing to act as the third investment banking firm hereunder, one of which firms shall be selected by lot by the Parties. The cost of such
third investment banking firm shall be borne [*]. 
  
 (d) The purchase and sale of a Purchase Interest pursuant to this Section 12.3 shall be transferred free and clear of all liens and other encumbrances and shall be consummated at closing at the principal
offices of the Notifying Party, on a Business Day within forty-five (45) days following the final determination of the Purchase Price, and upon at least ten (10) Business Days’ prior notice by the Notifying Party; provided that such period
shall be extended for such period of time as shall be necessary in order to obtain requisite governmental or regulatory approvals. At such closing, the Notifying Party shall pay the Breaching Party the Purchase Price by wire transfer of immediately
available funds. The Parties shall execute and deliver appropriate documentation, in form and substance that is reasonably acceptable, to effect the transfer of the Purchased Interest and each Party further agrees to reasonably cooperate to effect
the orderly transition of any activities then being conducted by the Breaching Party and its Affiliates pursuant to this Agreement and the US Agreement. 
  
 (e) The rights of the Parties set forth in this Section 12.3 are not exclusive and are in addition to any other rights or remedies
available to such Party under this Agreement or the US Agreement, at law or in equity. 
  
 12.4 Other Termination by Shire. At any time after the date of first Regulatory Approval of a Collaboration Product in the US Territory, Shire may terminate this Agreement effective upon [*]
advance written notice to New River. Termination by Shire pursuant to this Section 12.4 may be on the basis of the countries of the European Union and/or the ROW Territory (other than the countries of the European Union). In the event of termination
under this Section 12.4 no payment shall be due on account of such termination. In addition, this Agreement shall be automatically terminated in the event that Shire terminates the US Agreement pursuant to Section 13.4.2 of the US Agreement.

  
 12.5 Other Termination By New River. New River
may terminate this Agreement on the basis of (i) the countries of the European Union and/or (ii) the ROW Territory (other than 

  

 - 51 - 

 
the countries of the European Union), in each case by [*] advance written notice to Shire [*], other than the following products: (i) any
Collaboration Product, (ii) any product marketed by or on behalf of Shire as of the Effective Date, as set forth on Exhibit E, and any additional dosage strengths or line extensions thereof, and (iii) those products identified by Shire’s
internal nomenclature as [*], each as described on Exhibit E, it being understood that each such product [*] [*] [*]. For avoidance of doubt, New River shall have no right to terminate this Agreement pursuant to
this Section 12.5 if Shire files for Regulatory Approval for, or Commercializes, that product identified by Shire’s internal nomenclature as [*] or any [*] as such products do not contain [*] formulated for [*]
[*] for the treatment or prevention of ADHD and are therefore outside the scope of this Section 12.5. In the event of termination under this Section 12.5, no payment shall be due by New River to Shire on account of such termination. 

 
 12.6 Termination for Government Action. 
  
 12.6.1 During the period from the Effective Date and
expiring on [*] [*], either Party may terminate this Agreement upon written notice to the other Party at any time, if during such time there is a decree, judgment, injunction, order, or action that restricts, prevents or prohibits the
transactions contemplated by this Agreement under applicable Law in the European Union; provided that no such termination shall occur for a period of [*] following the entry of such decree, judgment, injunction, order or action (which period
shall be reduced to [*] if [*] in the US Territory for a Collaboration Product for an ADHD indication occurs after [*]), during which period of time the Parties shall cooperate and use reasonable commercial efforts to respond to
any government requests for information, and to contest and resist any such decree, judgment, injunction, order or action and to have vacated, lifted, reversed, stayed or overturned any such decree, judgment, injunction, order or action. In
addition, this Agreement may be terminated by either Party in the event that the US Agreement terminates pursuant to Section 13.6 thereof, irrespective of whether there is any decree, judgment, injunction, order, or action that restricts, prevents
or prohibits the transactions contemplated by this Agreement. 
  
 12.6.2 If such termination is effective prior to the FDA acceptance of the first, and only the first, Drug Approval Application for Collaboration Product for ADHD in the Field in the US Territory, [*]
[*], New River shall reimburse Shire [*] of the amount paid by Shire pursuant to Section 6.1. Such payment shall be made within [*] following termination; provided, that interest shall accrue beginning on the [*] after
termination at the rate provided for in Section 7.1. 
  
 12.6.3 If such termination is effective after the FDA acceptance of the first, and only the first, Drug Approval Application for Collaboration Product for ADHD in the Field in the US Territory, [*] New River shall reimburse
Shire (a) [*] of the amount paid by Shire pursuant to Section 6.1, and (b) [*] [*] of all other amounts paid by Shire pursuant to Section 6.2. Such payment shall be made within [*] following termination; provided, that
interest shall accrue beginning on the [*] after termination at the rate provided for in Section 7.1. 
  

 - 52 - 

 ARTICLE 13 
 EFFECTS OF TERMINATION 
  
 13.1 Post-Termination Activities by Shire. Without limiting any other legal or equitable remedies that New River may have, if this Agreement is terminated in accordance with Sections 8.8, 12.4, 12.5 or 12.6, or if this
Agreement is terminated in accordance with Section 12.3 and Shire is the Breaching Party, then the following provisions shall apply: 
  
 13.1.1 Assignments. Shire will promptly (and in each case within sixty (60) days of receipt of New River’s request) and
at no cost to New River (other than the Purchase Price, in the event of a termination pursuant to Section 12.3): 
  
 (a) upon New River’s request, assign to New River all of Shire’s right, title and interest in and to any agreements
between Shire and Third Parties that are freely assignable by Shire and that relate solely to the Development or Manufacture of any Compound or Collaboration Product in any territory for which such termination is effective; 
  
 (b) assign to New River all of Shire’s right,
title and interest in and to any Shire Marks (including any goodwill associated therewith), any registrations and design patents for any of the foregoing and any Internet domain name registrations for such trademarks and slogans, all to the extent
solely related to a Collaboration Product in any territory for which such termination is effective; 
  
 (c) assign to New River, to the extent freely assignable by Shire, the management and continued performance of any clinical trials
for the Collaboration Products ongoing as of the effective date of such termination in any territory for which such termination is effective; 
  
 (d) transfer to New River all of Shire’s right, title and interest in and to any and all regulatory filings and Regulatory
Approvals Controlled by Shire for the Collaboration Products in any territory for which such termination is effective, and grant New River the right to reference any regulatory filings and Regulatory Approvals Controlled by Shire for the
Collaboration Products elsewhere in the world for the purpose of Developing and Commercializing Collaboration Products in the territory for which such termination is effective; 
  
 (e) to the extent that any agreement or other asset described in this Section 13.1.1 is not
assignable by Shire or does not relate solely to Compound or a Collaboration Product, then such agreement or other asset will not be assigned, and upon the request of New River, Shire will take such steps as may be necessary to allow New River to
obtain and to enjoy the benefits of such agreement or other asset in the form of a license or other right to the extent Shire has the right and ability to do so; and 
  
 (f) provide copies of any other books, records, documents and instruments to the extent related to
Compound or Collaboration Product. 
  

 -53- 

 13.1.2 Manufacturing Activities. Shire will: 
  
 (a) upon New River’s request, if Shire is then
Manufacturing a Collaboration Product, supply New River with clinical and commercial quantities of such Collaboration Product for the shorter of (i) the period until New River or its designee has established and validated a manufacturing process for
such Collaboration Product and is approved to Manufacture clinical trial and commercial supplies of such Collaboration Product or (ii) eighteen (18) months from the effective date of such termination; provided, however, that New River will
[*] (as determined pursuant to Exhibit A hereof) with respect to such Collaboration Product; and 
  
 (b) if Shire is then Manufacturing a Collaboration Product, transfer the completed manufacturing process (together with any unique
mold or tooling used solely in connection therewith) for such Collaboration Product to New River or its designee upon New River’s request and at [*] cost and expense, and shall cooperate with New River to effect the transition of such
Manufacturing responsibilities. 
  
 13.1.3
License Grant. Shire agrees to grant and hereby grants to New River, effective upon such termination of this Agreement, an exclusive, royalty-free right and license, with the right to sublicense and authorize the grant of further
sublicenses, under any Shire Collaboration Patents and Shire’s rights and interest in the Joint Collaboration Patents to make, have made, use, sell, offer for sale, and import Compound or Collaboration Products affected by such termination in
the Field and in the territory for which such termination is effective; provided, however, that New River will be responsible for any payments associated with the grant of any license pursuant to the preceding sentence (including, without
limitation, any royalty or other payment obligations to an upstream licensor of any such Patents). In addition, if any Shire Know-How or technology claimed in a Shire Background Patent is then used in connection with the Manufacture, Development or
Commercialization of Compound or a Collaboration Product in the applicable territory, Shire agrees to grant and hereby grants to New River, effective upon such termination of this Agreement, a non-exclusive, royalty-free right and license, with the
right to grant sublicenses, under such Shire Background Patents and Shire Know-How, to make, have made, use, sell, offer for sale, and import Collaboration Products in the Field and in the territory for which such termination is effective. Finally,
Shire agrees to grant and hereby grants to New River, effective upon such termination of this Agreement, a non-exclusive, royalty-free right and license, with the right to grant sublicenses, under any copyright or Shire Confidential Information
embodied in or relating to any marketing plan, package inserts, or other Promotional Materials relating solely to Collaboration Products in the applicable territory. 
  
 13.1.4 Disclosure and Delivery. Shire will transfer to New River any Shire Collaboration
Know-How and Shire Background Know-How, to the extent then used in connection with the Manufacture, Commercialization or Development of the Collaboration Products; such transfer shall be effected by the delivery of documents, to the extent such
Know-How is embodied in documents, and to the extent that such Know-How is not fully embodied in documents, Shire shall make its employees and agents who have knowledge of such Know-How in addition to that embodied in documents available to New
River for interviews, demonstrations 

  

 - 54 - 

 
and training to effect such transfer in manner sufficient to enable New River to practice such Know-How as theretofore practiced by Shire. 
  
 13.1.5 Sublicensees. Each of Shire’s
sublicensees with respect to any affected Collaboration Products in any affected country at such time will continue to have the rights and license set forth in their sublicense agreements, subject to the continued performance of the obligations
thereunder; provided, however, that such sublicensee agrees in writing that New River is entitled to enforce all relevant terms and conditions of such sublicense agreement directly against such sublicensee; and provided, further, that such
sublicensee is not then in breach of its sublicense agreement. 
  
 13.1.6 Disposition of Inventory. New River shall have the option, exercisable within thirty (30) days following the effective date of such termination, to purchase any inventory of Collaboration Products
affected by such termination at Shire’s Cost of Goods therefor. New River may exercise such option by written notice to Shire during such thirty (30)-day period. Upon such exercise, the Parties will establish mutually agreeable payment and
delivery terms for the sale of such inventory. If New River does not exercise such option during such thirty (30)-day period, or if New River provides Shire with written notice of its intention not to exercise such option, then Shire and its
Affiliates and sublicensees will be entitled, during the period ending on the last day of the sixth (6th) full month following the effective date of such termination, to sell any inventory of Collaboration Products affected by such termination that
remain on hand as of the effective date of the termination, so long as Shire pays to New River the royalties applicable to said subsequent sales, with respect to sales in the ROW Territory, in accordance with the terms and conditions set forth in
this Agreement. 
  
 13.2 Post-Termination Activities by
New River. Without limiting any other legal or equitable remedies that Shire may have, if this Agreement is terminated in accordance with Section 12.3 and New River is the Breaching Party, then the following provisions shall apply: 

 
 13.2.1 Assignments. New River will promptly
(and in each case within sixty (60) days of receipt of Shire’s request) and at no cost to Shire (other than the Purchase Price, in the event of a termination pursuant to Section 12.3): 
  
 (a) upon Shire’s request, assign to Shire all of
New River’s right, title and interest in and to any agreements between New River and Third Parties that are freely assignable by New River and that relate solely to the Development or Manufacture of any Compound or Collaboration Products;

  
 (b) assign to Shire all of New
River’s right, title and interest in and to any New River Marks (including any goodwill therewith), including any registrations and design patents for the foregoing and any Internet domain name registrations for such trademarks and slogans, all
to the extent solely related to a Collaboration Product; 
  
 (c) assign to Shire, to the extent freely assignable by New River, the management and continued performance of any clinical trials for Collaboration Products ongoing as of the effective date of such
termination; 
  

 - 55 - 

 (d) transfer to Shire all of New River’s right, title and interest in and to
any and all regulatory filings and Regulatory Approvals Controlled by New River for Collaboration Products; 
  
 (e) to the extent that any agreement or other asset described in this Section 13.2.1 is not assignable by New River or does not
relate solely to Compound or a Collaboration Product, then such agreement or other asset will not be assigned, and upon the request of Shire, New River will take such steps as may be necessary to allow Shire to obtain and to enjoy the benefits of
such agreement or other asset in the form of a license or other right to the extent New River has the right and ability to do so; and 
  
 (f) provide copies of any other books, records, documents and instruments to the extent related to Compound or Collaboration
Product. 
  
 13.2.2 Manufacturing
Activities. New River will: 
  
 (a)
upon Shire’s request, if New River is then Manufacturing Compound or Collaboration Product, supply Shire with clinical and commercial quantities of such Compound or Collaboration Product for the shorter of (i) the period until Shire or its
designee has established and validated a manufacturing process for such Compound or Collaboration Product and is approved to Manufacture clinical trial and commercial supplies of such Compound or Collaboration Product or (ii) eighteen (18) months
from the effective date of such termination; provided, however, that Shire [*] [*] (as determined pursuant to Exhibit A hereof) for such Compound or Collaboration Product; and 
  
 (b) if New River is then Manufacturing Compound or
Collaboration Product, transfer the completed manufacturing process (together with any unique mold or tooling used solely in connection therewith) for such Compound or Collaboration Product to Shire or its designee upon Shire’s request and at
[*] cost and expense, and cooperate with Shire to effect the transition of such Manufacturing responsibilities. 
  
 13.2.3 License Grant. Each license granted by New River to Shire pursuant to Section 8.1 shall, effective upon such
termination of this Agreement, become an exclusive, perpetual, non-terminable, royalty-free right and license, with the right to sublicense and authorize the grant of further sublicenses, and shall include the right to Manufacture Compound.

  
 13.2.4 Disclosure and Delivery.
New River shall transfer to Shire any Licensed Know-How, to the extent then used in connection with the Manufacture, Commercialization or Development of the Collaboration Products; such transfer shall be effected by the delivery of documents, to the
extent such Know-How is embodied in documents, and to the extent that such Know-How is not fully embodied in documents, New River shall make its employees and agents who have knowledge of such Know-How in addition to that embodied in documents
available to Shire for interviews, demonstrations and training to effect such transfer in manner sufficient to enable Shire to practice such Know-How as theretofore practiced by New River. 
  
 13.2.5 Sublicensees. Each of New River’s
sublicensees with respect to any affected Collaboration Products at such time will continue to have the rights and license set forth in their sublicense agreements, subject to the continued performance of the obligations 

  

 - 56 - 

 
thereunder; provided, however, that such sublicensee agrees in writing that Shire is entitled to enforce all relevant terms and conditions of such sublicense
agreement directly against such sublicensee; and provided, further, that such sublicensee is not then in breach of its sublicense agreement. 
  
 13.2.6 Disposition of Inventory. Shire shall have the option, exercisable within thirty (30) days following the effective
date of such termination, to purchase any inventory of Compound or Collaboration Products at New River’s Cost of Goods therefor. Shire may exercise such option by written notice to New River during such thirty (30) day period. Upon such
exercise, the Parties will establish mutually agreeable payment and delivery terms for the sale of such inventory. 
  
 13.3 Accrued Rights. Termination of this Agreement for any reason will be without prejudice to any rights that will have accrued to the
benefit of a Party prior to the effective date of such termination. Such termination will not relieve a Party from obligations that are expressly indicated to survive the termination of this Agreement. 
  
 13.4 Confidential Information. Any Confidential Information
assigned pursuant to this Article 13 by the non-terminating Party shall thereafter be considered Confidential Information of the terminating Party and may be used by the terminating Party without regard to the restrictions otherwise imposed by
Article 9. 
  
 13.5 Survival. The following Articles
and Sections, together with any definitions used or exhibits referenced therein, will survive any termination or expiration of this Agreement: Sections 4.8.2, 4.8.3, 4.8.4, 7.6, 10.1, 10.9.3, 10.9.6, 11.4, 11.5, 11.6, 12.3.5, 15.2, and 15.4, and
Articles 9, 13, 14 (as to activities arising prior to the termination), and 16. 
  
 13.6 Liability Following Termination. In the event that either Party has rights to a Collaboration Product following termination of this Agreement, such Party shall be solely responsible for all
liabilities associated with such Collaboration Product arising after the effectiveness of such termination. 
  
 ARTICLE 14 
 INDEMNIFICATION; INSURANCE 
  
 14.1 Indemnification. 
  
 14.1.1 Indemnification by Shire. Shire hereby
agrees to save, defend and hold New River, its Affiliates, and their respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all charges, complaints, actions, suits, proceedings,
hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a Third Party (each a “Third Party Claim”) resulting directly from [*] by [*] of any [*] pursuant to this
Agreement[*] the [*] by [*] or its [*] or their [*] in [*] [*] under this Agreement[*] of Collaboration Products [*] except for [*] [*] as [*] under [*], or
[*] in connection with [*] [*] hereunder; in each case except to the extent that such Losses result from the negligence or willful misconduct of New River. 
  

 - 57 - 

 14.1.2 Indemnification by New River. New River hereby agrees to save,
defend and hold Shire, its Affiliates, and their respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Third Party Claims resulting directly from [*] by [*] of
any [*], [*] the [*] or [*] [*] by [*] or its [*] or their [*], [*] in [*] under this Agreement, [*], [*] or [*] of [*] [*] [*] or
[*] [*] hereunder; in each case except to the extent that such Losses result from the negligence or willful misconduct of Shire. 
  
 14.1.3 The rights of indemnification under this Section 14.1 shall be subject to the provisions of Sections 14.2 through 14.8.

  
 14.2 Notice of Claim. All indemnification claims
in respect of any indemnitee seeking indemnity under Section 14.1 (collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by the corresponding Party (the “Indemnified Party”).
The Indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon which such Indemnified
Party intends to base a request for indemnification under Section 14.1, but in no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such Third
Party Claim. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim
Notice, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. The Indemnifying Party shall not be
obligated to indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party materially prejudices the defense of such Third Party Claim. 
  
 14.3 Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim
subject to indemnification as provided for in Sections 14.1.1 and 14.1.2 by giving written notice to the Indemnified Party within [*] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of
a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party will not be
liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 
  
 14.4 Right to Participate in Defense. Without limiting Section
14.3, any Indemnitee will be entitled to participate in, but not control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such
employment will be at the Indemnitee’s own expense unless (a) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in
accordance with Section 14.3 (in which case the Indemnified Party will control the defense). 
  
 14.5 Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to
injunctive or other relief or otherwise adversely affect the business of the 

  

 - 58 - 

 
Indemnitee in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the
Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided,
however that such terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto), and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay
prior to the time of the entry of judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 14.3, the Indemnifying Party
will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s
reasonable discretion). The Indemnifying Party that has assumed the defense of the Third Party Claim in accordance with Section 14.3 will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the
written consent of such Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third
Party Claim without first offering to the Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with Section 14.3. 
  
 14.6 Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will, and will cause
each other Indemnitee to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection with such Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information
that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the
Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 
  
 14.7 Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the
Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 
  
 14.8 Treatment of Certain Losses. New River shall be solely responsible for all Losses from Third Party Claims
resulting directly from either (a) the use or administration of the Compound by New River prior to the Effective Date or (b) the conduct of clinical testing of the Compound by New River (including such clinical tests that commenced prior to and
continuing after the Effective Date). 
  

 - 59 - 

 14.9 Insurance. Each Party will obtain and keep in force, through self insurance or
otherwise, in a form reasonably acceptable to the other Party hereto, insurance in scope and amount as required by law applicable to a Party’s activities hereunder and such additional amounts as may be reasonably necessary to cover such
Party’s indemnity obligations under this Agreement with scope and coverage as is normal and customary in the biotechnology/pharmaceutical industry generally for parties similarly situated. It is understood that such insurance will not be
construed to limit a Party’s liability with respect to its indemnification obligations under this Article 14. Each Party will, except to the extent self insured, provide to the other Party upon request a certificate evidencing the insurance
such Party is required to obtain and keep in force under this Article 14. Such certificate will provide that such insurance will not expire or be cancelled or modified without at least thirty (30) days’ prior notice to the other Party.

  
 14.10 Guaranty. In consideration of the rights
granted to Shire under this Agreement, and to induce New River to enter into this Agreement, Shire Pharmaceuticals Group PLC hereby unconditionally guarantees in favor of New River the full payment and performance by Shire of all obligations of
Shire under this Agreement, in accordance with the terms and conditions of this Agreement, including any applicable notice or cure periods. This guaranty shall be enforceable after the failure by Shire to perform any obligation it may have under
this Agreement in accordance with its terms, and shall be effective regardless of the solvency or insolvency of Shire at any time, the extension or modification of the obligations of this Agreement by operation of law, or the subsequent
reorganization, merger, consolidation or other restructuring of Shire. Shire Pharmaceuticals Group PLC hereby expressly waives any requirement that New River exhaust any right, power or remedy under Article 15, or proceed against any other Shire
entity under Article 15, for any obligation or performance hereunder prior to proceeding directly against Shire Pharmaceuticals Group PLC under this Section 14.10. 
  
 ARTICLE 15 
 DISPUTE RESOLUTION 
  
 15.1
Disputes. For all matters other than those delegated to the JDC or JSC under this Agreement, the Parties hereby agree that the dispute shall be referred to a senior executive of New River and a senior executive of Shire (the
“Representatives”). If any such matter has not been resolved within [*] of such referral to the Representatives either Party may invoke the provisions of Section 15.2 for such dispute. No dispute resolution procedure set
forth in this Agreement shall be construed as an agreement to arbitrate under any federal or state arbitration law, including but not limited to the Federal Arbitration Act, and shall not deprive a court of competent jurisdiction from resolving any
dispute arising under, or related to, this Agreement. In the event of any dispute between the Parties arising in connection with Article 10 of this Agreement, the Parties agree that the dispute resolution described under this Article 15 will be
conducted with sufficient dispatch to prevent loss of patent rights in the disputed subject matter. 
  
 15.2 Litigation. Any dispute that is not resolved as provided in the preceding Section 16.1, whether before or after termination of this
Agreement, may be submitted by either Party only to any court of competent jurisdiction in the United States. 
  

 - 60 - 

 15.3 Injunctive Relief. Notwithstanding anything to the contrary in this Agreement, either
Party will have the right to seek temporary injunctive relief in any court of competent jurisdiction as may be available to such Party under the laws and rules applicable in such jurisdiction with respect to any matters arising out of the other
Party’s performance of its obligations under this Agreement. 
  
 15.4 Governing Law. Resolution of all disputes arising out of or related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and
construed under the substantive laws of the State of New York, without regard to conflicts of law rules that would provide for application of the law of a jurisdiction outside New York. 
  
 ARTICLE 16 
 MISCELLANEOUS 
  
 16.1 Entire Agreement;
Amendment. This Agreement, together with the US Agreement, including the exhibits attached hereto and thereto (each of which is hereby and thereby incorporated herein and therein by reference), sets forth the complete, final and exclusive
agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements (including the January Agreement) and understandings
between the Parties, except for the Existing NDA, which will continue to govern the obligations of the Parties with respect to information disclosed thereunder with respect to periods prior to the Effective Date, and the Material Transfer Agreement
between Shire Pharmaceuticals Inc. and New River dated January 7, 2005. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth
herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance of doubt, the Parties agree that all
covenants, promises, agreements, warranties, representations, conditions, and understandings set forth herein are made and deemed effective as of the Effective Date, notwithstanding the execution of this Agreement and the US Agreement, and that the
execution of this Agreement and the US Agreement shall not constitute a waiver of any right or claim of either Party as of the Effective Date. 
  
 16.2 Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming
Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including without limitation, an act of God, voluntary or involuntary compliance with
any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like
catastrophe; provided, however, the payment of invoices due and owing hereunder shall not be delayed by the payer because of a force majeure affecting the payer, unless such force majeure specifically precludes the payment process. 
  

 - 61- 

 16.3 Notices. All notices or other communications that are required or permitted under this
Agreement will be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses
below. Any such communication will be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal delivery or overnight courier as provided in this
Agreement), and (b) on the second Business Day after dispatch, if sent by internationally-recognized overnight courier. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 
  

			
	For New River:	  	New River Pharmaceuticals Inc.
	 	  	The Governor Tyler
	 	  	1881 Grove Avenue
	 	  	Radford, VA 24141
	 	  	Phone: (540) 633-7978
	 	  	Fax: (540) 633-7939
	 	  	Attention: President
		
	with a copy to:	  	Cooley Godward LLP
	 	  	5 Palo Alto Square
	 	  	3000 El Camino Real
	 	  	Palo Alto, CA 94306-2155
	 	  	Phone: (650) 843-5000
	 	  	Fax: (650) 849-7400
	 	  	Attention: Robert L. Jones
		
	For Shire:	  	Shire Pharmaceuticals Ireland Limited
	 	  	2nd Floor, Unit 1A
	 	  	Citylink Business Park
	 	  	Old Naas Road
	 	  	Dublin 12
	 	  	IRELAND
	 	  	Fax: 011 353 1 429 7701
	 	  	Attention: General Counsel
		
	 	  	Shire Pharmaceuticals Group plc
	 	  	Hampshire International Business Park
	 	  	Chineham, Basingstoke
	 	  	Hampshire, RG24 8EP
	 	  	ENGLAND
	 	  	Fax: 011 44 125 689 4710
	 	  	Attention: General Counsel
		
	 	  	Shire Pharmaceuticals
	 	  	725 Chesterbrook Boulevard
	 	  	Wayne, Pennsylvania 19087-5637
	 	  	Fax: (484) 595-8163
	 	  	Attention: General Counsel

  

 - 62 - 

			
	with a copy to:	  	Morgan, Lewis & Bockius LLP
	 	  	502 Carnegie Center
	 	  	Princeton, NJ 08540
	 	  	Fax: (609) 919-6701
	 	  	Attention: Randall B. Sunberg

  
 16.4
Independent Contractors. In making and performing this Agreement, Shire and New River shall act at all times as independent contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an
agency, partnership, limited partnership, joint venture or employer and employee relationship between Shire and New River and this Agreement shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any
charges or expenses for or in the name of the other Party. Except as otherwise provided in this Agreement, each Party shall be solely responsible for its own costs and expenses associated with this Agreement. 
  
 16.5 Non-Solicitation. From and after the Effective Date until
[*] the termination or expiration of this Agreement, neither Party shall, and shall cause each of its Affiliates not to, directly or indirectly, without the other Party’s prior written consent, solicit the employment of any
employee (or former employee bound by a non-competition obligation) of the other Party or its Affiliates with whom it has come in contact in conducting activities under this Agreement; provided, however, that the foregoing provisions shall not apply
to (a) a general advertisement or solicitation program that is not specifically targeted at such persons or (b) the solicitation of any employee after such time as such employee’s employment has been terminated by the other Party or its
Affiliate. 
  
 16.6 Maintenance of Records. Each
Party shall keep and maintain all records required by Law with respect to Products and shall make copies of such records available to the other Party upon reasonable request. 
  
 16.7 United States Dollars. References in this Agreement to “Dollars” or “$” shall mean
the legal tender of the United States of America. 
  
 16.8
No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party. 
  
 16.9 Assignment. Neither Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by
operation of Law or otherwise, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other Party (which consent may be granted, withheld or conditioned at such other Party’s sole and
absolute discretion); provided, however, that either Party may assign or transfer this Agreement or any of its rights or obligations under this Agreement without the consent of the other Party (a) to any Affiliate of such Party, or (b) to any Third
Party with which it merges or consolidates, or to which it transfers all or substantially all of its assets. The assigning Party (unless it is not the surviving entity) will remain jointly and severally liable with, and will guarantee the
performance of, the relevant Affiliate or Third Party assignee under this 

  

 - 63 - 

 
Agreement, and the relevant Affiliate assignee, Third Party assignee or surviving entity will assume in writing all of the assigning Party’s obligations
under this Agreement. Any purported assignment or transfer in violation of this Section 16.9 will be void ab initio and of no force or effect. 
  
 16.10 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Signatures provided by facsimile transmission shall be deemed to be original signatures. 
  
 16.11 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may
be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 16.12 Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the
provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable
one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 
  
 16.13 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be
deemed to have authored the ambiguous provision. 
  
 16.14
Headings. The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or
section. 
  
 16.15 No Waiver. Any delay in enforcing
a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an
express written and signed waiver as to a particular matter for a particular period of time. 
  
 [Signature Page Follows.] 
  

 - 64 - 

 IN WITNESS WHEREOF, the Parties have executed this ROW Territory License Agreement in duplicate
originals by their proper officers as of the date first written above. 
  

											
	NEW RIVER PHARMACEUTICALS INC.	 	 	 	SHIRE PHARMACEUTICALS IRELAND LIMITED
					
	By:	 	 /s/ Randal J. Kirk
	 	 	 	By:	 	 /s/ Matthew Emmens

	 	 	 Randal J. Kirk
	 	 	 	 	 	 Name:
	 	 Matthew Emmens

	 	 	 Chief Executive Officer
	 	 	 	 	 	 Title:
	 	 CEO

			
	 	 	 	 	SHIRE PHARMACEUTICALS GROUP PLC
					
	 	 	 	 	 	 	By:	 	 /s/ Matthew Emmens

	 	 	 	 	 	 	 	 	 Name:
	 	 Matthew Emmens

	 	 	 	 	 	 	 	 	 Title:
	 	 CEO

  

  
 EXHIBIT A 

 
 DETERMINATION OF CERTAIN ACCOUNTING TERMS 
  
 Upon the request of either Party from time to time, each Party will reasonably consider
suggestions from the other Party to review and clarify and possibly expand any of the definitions in this Exhibit A or any of the financial terms defined in Article 1, including financial terms whose definition is referred to in the table at
the end of Article 1; provided that no changes shall be made without the written consent of both Parties. 
  

	1.	COST OF GOODS SOLD 

  
 The provisions of this section shall govern the determination of the cost of a unit of Compound or Collaboration Product. The accumulated costs of such
unit as determined hereunder shall be referred to as “Cost of Goods.” When such unit is sold or transferred to Shire, in the case of New River, or to a Third Party, in the case of Shire, the Cost of Goods of such unit shall become the
unit’s Cost of Goods Sold, subject to the selling Party’s inventory flow methods adopted. 
  

	 	1.1.	New River’s Cost of Goods. If the Manufacture of Compound and/or Collaboration Product is performed, in any part, by one or more Third Party Manufacturer(s) on
behalf of New River, New River’s Cost of Goods shall equal [*] 

  

	 	1.2.	Shire’s Cost of Goods. Relating to Collaboration Product transferred to it from New River, Shire’s Cost of Goods shall equal [*]

  

	 	1.3.	Compound and/or Collaboration Product Manufactured by a Party. If the Manufacture of Compound and/or Collaboration Product is performed directly by a Party, the Party
conducting such activities may propose to the other Party a methodology to determine the Cost of Goods pursuant to a cost accounting system based on standard costs, and the Parties shall negotiate in good faith to agree upon such methodology. The
Parties agree and acknowledge that, if New River undertakes to Manufacture Compound and/or Collaboration Product directly, [*] by the Parties in determining New River’s Cost of Goods. Similarly, if Shire undertakes to Manufacture
Collaboration Product directly (pursuant to Shire’s rights under the Agreement), [*] by the Parties in determining Shire’s Cost of Goods. 

  

	 	1.4.	 Cost Adjustments. If any adjustment to New River’s Cost of Goods of a particular quantity of Compound and/or Collaboration Product arises by way
of any adjustment to New River’s actual costs incurred and payable to a Third Party Manufacturer subsequent to the transfer of such quantity to Shire, New River shall promptly notify Shire of such adjustment and the 

  

	 	 
Parties shall reflect such adjustment for all applicable purposes under this Agreement. 

  

	2.	ALLOCATION OF COSTS. 

  
 Except as it relates to appropriately allocating an item of expense or cost to more than one category of expense or cost under this Agreement, no item of
expense or cost shall be treated as being a part of more than one category of expense or cost under this Agreement. 
  

  
 EXHIBIT B 

 
 ADDITIONAL SUPPLY TERMS 
  
 The following sets forth an outline of the principal terms of a supply agreement (the
“Supply Agreement”) to be negotiated pursuant to Section 5.4 of the ROW Territory License Agreement. In each case, the terms hereof and of the Supply Agreement will be subject to the Parties’ rights and obligations under the ROW
Territory License Agreement. 
  
 1. Delivery. Compound or Collaboration
Product supplied by New River to Shire shall be delivered to a facility designated by Shire and otherwise in accordance with the applicable Third Party Manufacturer Agreement. 
  
 2. Shortage of Materials. 
  

	 	(a)	In the event that the materials and/or resources required to manufacture and deliver Compound or Collaboration Product to Shire in a timely manner are, or are reasonably anticipated
to become, in short supply such that New River may be unable to provide Shire with the quantities of Compound or Collaboration Product forecast by Shire under the Supply Agreement, New River shall notify Shire of such shortage as promptly as
practicable. If New River so notifies Shire, New River and Shire shall promptly meet to discuss how to address the potential shortage. 

  

	 	(b)	In the event that New River, at any time, has any information indicating that it may not be able to supply Shire with all forecasted or ordered quantities of Compound or
Collaboration Product (whether or not New River may be at fault), New River shall immediately provide Shire a written notice to that effect. 

  
 3. Quality Assurance. The Parties shall enter into a Quality Agreement (the “Quality Agreement”) which shall set forth certain obligations of each Party
regarding the manufacture and supply of Compound or Collaboration Product. As more specifically set forth in the Quality Agreement, New River shall be responsible for all aspects of its supply chain regarding the Compound or Collaboration Product,
including without limitation quality control, quality assurance, release testing and stability testing. 
  
 4. Specifications. The specifications for Compound or Collaboration Product, including the necessary documentation, certificates of analysis and test results, will be established according to the procedures set
forth in the Collaboration Agreement. 
  
 5. Location of Manufacturing.
[*] Should New River desire to change any of the manufacturing sites for Compound or Collaboration Product, or any component thereof, to a site other than those designated in the applicable Regulatory Approval, New River shall notify Shire in
writing and the Parties shall thereafter meet to discuss the potential consequences of such a change. [*] 
  

 6. Back-Up Manufacturing Rights. If New River fails to supply at least [*] [*] of Shire’s
requirements for a Collaboration Product [*] [*] (a “Failure to Supply”), then Shire may, by providing written notice [*] [*] of the occurrence of such Failure to Supply, elect to assume manufacturing of such
Collaboration Product. If Shire elects to assume the manufacturing of a Collaboration Product (or if Shire is a back-up manufacturer pursuant to Section 5.3), the following provisions shall be applicable: 
  

	 	(a)	Transfer of Manufacturing Technology. New River, [*], shall be responsible for providing Shire with the documentation, know-how and technical assistance necessary for
the successful implementation of the manufacturing process at a location to be designated by Shire. To the extent practicable, New River shall continue to supply Shire with its needs of Collaboration Product under the terms of the Supply Agreement
until Shire is capable of doing so. 

  

	 	(b)	Documentation to be Provided by New River. In particular, in connection with the transfer of the manufacturing technology for a Collaboration Product, New River shall provide
the following to Shire: 

  

	 	(i)	Copies of [*] related to manufacturing the Collaboration Product; 

  

	 	(ii)	A list of all [*] in the production of the Collaboration Product; 

  

	 	(iii)	Copies of all [*], for the Collaboration Product; 

  

	 	(iv)	Copies of all [*] 

  

	 	(v)	All necessary [*] necessary to manufacture the Collaboration Product and copies of any [*]; and 

  

	 	(vi)	Such other documentation as the Parties may agree. 

  

	 	(c)	Audit of New River Procedures. The Supply Agreement will contain reasonable and customary provisions allowing Shire to inspect and audit those portions of the sites at which
the Collaboration Product is manufactured in connection with the transfer of manufacturing technology for a particular Collaboration Product. Any information obtained by Shire through such inspections and audits or reviews of documentation shall be
treated as confidential information of New River, subject to the confidentiality obligations under Article 9. 

  

	 	(d)	Access to [*]. New River shall make available to Shire, for a reasonable period of time, all manufacturing and operations [*] necessary to support the transfer of the
manufacturing technology to Shire, including the [*] [*] for the validation and qualification of the transferred manufacturing protocol. These [*] in the implementation of the manufacturing technology until all Installation
Qualification, Operation Qualification and Process Qualification procedures have been completed successfully. 

  

 7. Forecasts. Following the execution of the Supply Agreement, Shire will give to New River a [*] rolling
forecast of Shire’s estimated monthly requirements of Compound or Collaboration Product. The first [*] of the forecast shall be binding and the remainder shall be a good faith estimate of Shire’s requirements. However, for each of
the [*] in each such forecast, although the quantities forecast may exceed [*] the supply obligations of New River shall not exceed [*] of the amount forecast for such month in the previous forecast. Shire will provide New River
with monthly binding purchase orders for Compound or Collaboration Product in accordance with the binding portion of the rolling forecast. 
  
 8. Quality Complaints. New River shall be primarily responsible for handling product quality complaints related to Compound or Collaboration Product. Each Party
shall promptly advise the other of any such quality complaints with respect to Compound or Collaboration Product. 
  
 9. Representations and Warranties. New River shall make, and shall cause its Affiliates to make, representations and warranties regarding the Compound or
Collaboration Product supplied under the Supply Agreement, including, without limitation, the following representations and warranties: 
  

	 	(a)	All Compound or Collaboration Product shall (i) be manufactured in accordance with the then-current good manufacturing practices of all applicable Regulatory Authorities in
countries reasonably designated by Shire from time to time, and all other applicable laws, at the time of delivery of Compound or Collaboration Product, (ii) comply with the specifications at the time of delivery. 

  
 In addition, for purposes of avoiding prosecution under the FD&C Act only, New River will
guarantee that any Compound or Collaboration Product delivered under the Supply Agreement (i) shall not be adulterated or misbranded within the meaning of the Act and applicable foreign equivalents at the time of delivery to Shire, and (ii) is not
an article that may not, under the Act (or applicable foreign equivalents), be introduced into interstate commerce. 
  
 10. Covenants. New River shall make, and shall cause its Affiliates to make, covenants relating to Compound or Collaboration Product supplied under the Supply
Agreement, including, without limitation, the following covenants: 
  

	 	(a)	New River shall, and require its Affiliates and Third Party contract manufacturers, if any, to maintain all regulatory and governmental permits, licenses and approvals that may be
necessary to manufacture and ship Compound or Collaboration Product. 

  

	 	(b)	New River shall advise Shire of any information that arises out of New River’s or its Affiliates’ or Third Party contract manufacturers’ activities of which it is
aware, that have adverse regulatory compliance and/or reporting consequences concerning Compound or Collaboration Product. 

  

	 	(c)	New River shall promptly advise Shire of any requests by any Regulatory Authority for inspections at the premises of New River or its Affiliates or Third Party contract
manufacturers, with respect to Compound or Collaboration Product. 

  

	 	(d)	In the event New River or its Affiliates or Third Party contract manufacturers are inspected by any Regulatory Authority relating to Compound or Collaboration Product, [*].
New River shall promptly notify Shire of any alleged violations or deficiencies relating to a facility at which Compound or Collaboration Product is manufactured, packaged or stored, and shall promptly disclose to Shire all relevant portions of any
notice of observations or potential violations as well as a copy of its or its Affiliates’ or Third Party contract manufacturers’ response thereto. 

  

	 	(e)	For the purpose of permitting a quality and compliance audit, New River shall grant to authorized representatives of Shire (or a Third Party hired on behalf of Shire who is
reasonably acceptable to New River), upon reasonable notice, access to areas of each of its plants, and permit Shire access to areas of New River’s and its Affiliates’ and, to the extent practicable, Third Party contract
manufacturers’ plants, at such times as Compound or Collaboration Product is being manufactured, packaged or tested; provided, that Shire’s audit of any Third Party facilities will be subject to reasonable and customary confidentiality and
non-use obligations. 

  

	 	(f)	Shire shall have the right to examine those technical records made by New River or its Affiliates or Third Party contract manufacturers that relate to the manufacture of Compound or
Collaboration Product; provided, that such records will be subject to reasonable and customary confidentiality and non-use obligations. 

  

	 	(g)	New River shall ensure that its Third Party contract manufacturers agree [*] 

  
 11. Nonconforming Goods. If a shipment of Compound or Collaboration Product fails, at the time of delivery, to comply with the
applicable specifications, and Shire notifies New River of such nonconformity [*] within [*] following Shire’s receipt of such shipment, then New River will replace, at no additional expense to Shire, such Compound or
Collaboration Product as soon as reasonably practicable after receipt of notification of nonconformity. Any dispute regarding whether a shipment of Compound or Collaboration Product conforms with the applicable specifications will be submitted to an
independent laboratory mutually acceptable to the Parties for final resolution. The costs of retaining the laboratory will be included in Cost of Goods for the US Territory and will be borne by the Party whose evaluation of the applicable shipment
of Compound or Collaboration Product is mistaken in the ROW Territory. 
  
 12.
Payment Terms. Shire will pay New River [*] for any quantity of Compound and Collaboration Product provided under the Supply Agreement. At the time of each shipment, New River shall invoice Shire, and Shire shall pay for such shipment
within [*] [*] of receipt of each such invoice. 
  
 13.
Additional Provisions. In addition to more detailed terms regarding the matters specified above in this Exhibit B, the Supply Agreement shall contain other customary supply agreement provisions. 
  

					
	 	 	 EXHIBIT C
  
 JOINT PRESS RELEASE
	 	

	 Shire Pharmaceuticals Group plc
  
 Hampshire International Business Park,
 Chineham, Basingstoke RG24 8EP
UK
 Tel +44 1256 894000 Fax +44 1256 894708
 http://www.shire.com
	 	 
	  
 New River Pharmaceuticals
  
 1881 Grove Avenue
 Radford, VA 24141
 Tel +1 540 633 7978 Fax: +1 540 633 7979
 http://www.nrpharma.com
	 	

  
 For immediate release 
  
 * (ET) * (GMT) 
  
 Shire and New River announce collaboration on Phase 3 ADHD drug candidate 
  
 BASINGSTOKE, UK, PHILADELPHIA, PA, US and RADFORD, Va., US January 31, 2005—
Shire Pharmaceuticals Group plc (LSE: SHP; NASDAQ: SHPGY; TSX: SHQ) and New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today the signing of an agreement for the global commercialization of NRP104, New River’s Phase 3 compound for
treatment of Attention Deficit Hyperactivity Disorder (ADHD), as well as for other potential indications. 
  
 Under the terms of the agreement the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the US. Shire will book the product sales and New River may supply up to 25% of the sales
effort under a co-promotion right. New River will be financially and operationally responsible for clinical and manufacturing development. 
  
 Upon U.S. Food and Drug Administration (FDA) approval, the parties will divide operating profit in accordance with the following general principles: Shire will retain 75%
of profits for the first two years following launch and the parties will share the profits equally thereafter. 
  
 In the rest of the world, Shire has a license to develop and commercialize NRP104 and New River will receive a low double-digit royalty on net sales. 
  

 Shire pays an initial sum of US$50 million on signing, a further US$50 million upon acceptance of filing of the New Drug
Application by the FDA and up to US$300 million in milestone payments depending on the characteristics of the FDA-approved product labeling. An additional US$100 million milestone would be payable as a sales bonus upon achieving a significant sales
target. Shire currently plans to expense the first two US$50 million payments, and to capitalize and amortize the milestone payments and the sales bonus over the life of the product. 
  
 Shire may be entitled to refunds of amounts previously paid in the event of a delayed product approval, or upon FDA approval depending on
the characteristics of the approved product labeling. 
  
 Matthew Emmens, Chief
Executive of Shire, said: 
  
 “This is a strong addition to our ADHD
portfolio and complements the development strategy of Shire and its pipeline. NRP104 is in late stage development and we are encouraged by the data that we have seen to date and hope that the new drug has similar efficacy of currently marketed ADHD
treatments with potential additional advantages. Importantly, NRP104 could become a global ADHD product. We have structured the financial payments for this collaboration to reflect the potential of the new drug and look forward to progressing this
product with New River.” 
  
 R.J. Kirk, Chairman and Chief Executive Officer
of New River, said: 
  
 “We are delighted to announce this collaboration with
Shire, a company that we believe will bring substantial value to this project as we plan and hopefully execute the commercialization of NRP104. Shire’s CNS expertise and leadership position in the ADHD market allows them to significantly
contribute to this collaboration in a manner that we believe will optimally serve the interests of our shareholders. We therefore believe that Shire will be our ideal partner for this product and we look forward to working with their outstanding
team to fully realize the potential of NRP104.” 
  
 For further
information please contact: 
  

					
	Shire Pharmaceuticals Group plc	 	 	 	 
			
	Investor Relations	 	 	 	 
			
	Cléa Rosenfeld (UK and Europe)	 	 	 	 +44 1256 894 160

			
	 Brian Piper (US and Canada)
	 	 	 	 +1 484 595 8252

  

					
	Media	 	 	 	 
			
	Jessica Mann (UK and Europe)	 	 	 	+44 1256 894 280
			
	 Matthew Cabrey (US)
	 	 	 	+1 484 595 8248

  

					
	New River Pharmaceuticals Inc.	 	 	 	 
			
	Investor Relations	 	 	 	 
			
	 John Quirk
	 	 	 	+1 646 536 7029
			
	jquirk@theruthgroup.com	 	 	 	 

  

					
	Media	 	 	 	 
			
	 Zack Kubow
	 	 	 	+1 646 536 7020
			
	zkubow@theruthgroup.com	 	 	 	 

  

 Notes to editors 
  
 Shire 
  
 Shire Pharmaceuticals Group Plc is a global pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the
areas of central nervous system, gastrointestinal and renal diseases. Shire has operations in the world’s key pharmaceutical markets (U.S., Canada, U.K., France, Italy, Spain and Germany). 
  
 For further information on Shire, please visit the Company’s website: www.shire.com

  
 “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995 
  
 Statements included herein that are not historical
facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially
affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization, the impact of competitive products,
including, but not limited to, the impact of those on Shire’s Attention Deficit & Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise, government
regulation and approval, including but not limited to the expected product approval dates of METHYPATCH® (methylphenidate) and NRP104, including its scheduling classification by the Drug Enforcement Agency in the United States, Shire’s ability to secure new products for development,
the implementation of the current reorganization and other risks and uncertainties detailed from time to time in Shire’s filings, including its Annual Report on Form 10-K for the year ended December 31, 2003, with the Securities and Exchange
Commission. 
  
 New River 
  
 New River Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing
novel pharmaceuticals that are safer and improved versions of widely-prescribed drugs, including amphetamines and opioids. 
  
 For further information on New River, please visit the company’s website at www.nrpharma.com. 
  
 “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 
  
 This press release contains certain forward-looking information that is intended to be
covered by the safe harbor for “forward-looking statements” provided by the Private 

  

 
Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),”
“feel(s),” “believe(s),” “will,” “may,” “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to
certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of New River Pharmaceuticals, that could cause actual results to differ materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties include: those discussed and identified in the New River Pharmaceuticals Inc. final prospectus filed on August 5, 2004, under Rule 424(b) of the Securities Act of 1933, as
amended; the ability to successfully execute the collaboration with Shire within a reasonable timeframe or at all; the progress of our product development programs; the status of our preclinical and clinical development of potential drugs, the
likely success of our drug products in clinical trials and the regulatory approval process, particularly whether and under what circumstances NRP104 will be approved by the FDA; the ability to develop, manufacture, launch and market NRP104; our
projections for future revenues, profitability and ability to achieve certain sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likely scheduling and labeling of NRP104; our ability to
attract partners with acceptable development, regulatory and commercialization expertise; the likelihood of regulatory approval under Section 505(b)(2) under the Federal Food, Drug, and Cosmetic Act; the expected benefits of NRP104 such as efficacy
and potential advantages; our ability to develop safer and improved versions of widely-prescribed drugs; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that
speak only as of the date hereof. New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. Readers are also urged to carefully review and consider the various disclosures in New River Pharmaceuticals’ final prospectus filed with the SEC on August 5, 2004, under Rule 424(b) of the Securities Act of 1933, as amended, as well as
other public filings with the SEC. 
  

 EXHIBIT D 
  

TECHNICAL TRADE SECRETS 
  
 Compound means the compound currently identified by New River as NRP104 with the chemical structure [*] and any isomers, salts, solvates,
polymorphs, esters and derivatives of any of the foregoing, in each case where an active moiety of such compound is [*]. 
  

  
 EXHIBIT E 

 
 CERTAIN PRODUCTS OF SHIRE 
  
 Development Projects 
  
 [*] 
  
 Marketed Stimulant Products 
  
 [*] 
  

  
 SCHEDULE 5.1.1

  
 NEW RIVER MANUFACTURING CONTRACTORS AND ACTIVITIES

  

			
	 NAME OF THIRD PARTY

	  	 ACTIVITIES PERFORMED / TO BE
PERFORMED

	 [*]
	  	Manufacture of Drug Substance (API)
		
	 [*]
	  	Manufacture of Drug product (formulation and encapsulation)

  

  
 SCHEDULE 11.1.3(b)

  
 INDs and DRUG APPROVAL APPLICATIONS 

 
 United States IND #67482 
 United States IND #70109 
  

  
 SCHEDULE
11.1.3(c)(i)(I) 
  
 LICENSED PATENTS [*] 

 

			
	 Serial No.
(Filing Date)

	  	 Next Action Date
(Official fees to be paid within 180 days)1

	[*]	  	[*]

	1	Official fees do not include Attorney or Foreign Associate Fees. 

  

  
 SCHEDULE
11.1.3(c)(i)(II) 
  
 LICENSED PATENTS THAT DO NOT CLAIM
COMPOUND OF COLLABORATION PRODUCTS 
  

			
	 Serial No.

 (Filing Date)

	  	 Next Action Date
 (Official fees to be paid within 180 days)

	[*]	  	[*]Form of Senior Note, Series D

 Exhibit 4.18 

					
			
	  	 	 	 	  
	(Date of Issuance)	 	 	 	 

  
 JPMorgan Chase & Co. , (the
“Issuer”), a corporation organized and existing under the laws of the [State or Commonwealth] of Delaware , for value received, hereby promises to pay to Cede & Co. or its registered assigns: (i) on each principal payment date,
including each amortization date, redemption date, repayment date, maturity date, and extended maturity date, as applicable, of each obligation identified on the records of the Issuer (which records are maintained by JPMorgan Chase Bank, National
Association (the “Paying Agent”)),* the principal amount then due and payable for each such obligation and (ii) on each interest payment date, if any, the interest then due and payable on the principal amount for each such obligation.
Payment shall be made by wire transfer of United States dollars to the registered owner, or in immediately available funds or the equivalent to a party as authorized by the registered owner and in the currency other than United States dollars as
provided for in each such obligation, by the Paying Agent without the necessity of presentation and surrender of this Master Note. 
  
 REFERENCE IS HEREBY MADE TO THE FURTHER PROVISIONS OF THIS MASTER NOTE SET FORTH ON THE REVERSE HEREOF, AND TO THE TERMS OF THE PROSPECTUS SUPPLEMENT AND PRICING
SUPPLEMENT(S), WHICH ARE INCORPORATED HEREIN BY REFERENCE. 
  
 This Master Note is
a valid and binding obligation of the Issuer. 
  
 IN WITNESS WHEREOF, the Issuer
has caused this instrument to be duly executed under its corporate seal. 
  

					
	ATTEST:	 	 	 	JPMorgan Chase & Co.
	 	 	 	 	(Issuer)
			
	  	 	 By:
	 	  
	(Signature)	 	 	 	(Authorized Officer’s Signature)
			
	  	 	 	 	  
	(Printed Name and Title)	 	 	 	(Printed Name and Title)
			
	  	 	 	 	[Seal]
	*as being evidenced by this Master Note	 	 	 	 
			
	  	 	 	 	Deutsche Bank Trust Company America
	 	 	 	 	(Trustee)
			
	  	 	 By:
	 	  
	 	 	 	 	(Authorized Officer’s Signature)
			
	  	 	 	 	  
	 	 	 	 	(Printed Name and Title)

			
	 This Master Note evidences indebtedness of the Issuer of a single Series
	  	  D                            
	 	  	 (Series Designator)

			
	 and Rank
	 	   **

	 	 	(Secured Senior or Junior, or Unsecured Senior, Senior Subordinated or Junior Subordinated)

 (the “Debt Obligations”), all issued or to be issued under and pursuant to an Indenture dated as of
December 1, 1989, as amended (the (Indenture”), duly executed and delivered by the Issuer to Deutsche Bank Trust Company Americas (formerly Bankers Trust Company), as trustee (the “Trustee”), to which Indenture and all
indentures supplemental thereto reference is hereby made for a description of the rights, duties, and immunities thereunder of the Trustee and the rights thereunder of the holders of the Debt Obligations. As provided in the Indenture, the Debt
Obligations may mature at different times, may bear interest, if any, at different rates, may be subject to different redemption provisions, if any, may be subject to different sinking, purchase or analogous funds, if any, may be subject to
different covenants and events of default, and may otherwise vary as in the Indenture provided or permitted. The Debt Obligations aggregated with any other indebtedness of the Issuer of this Series are limited (except as provided in the Indenture)
to the principal amount of $5,000,000,000 designated as the Medium-Term Notes of the Issuer Due 9 Months or more Years from Date of Issue. No reference herein to the Indenture and no provision of this Master Note or of the Indenture
shall alter or impair the obligation of the Issuer, which is absolute and unconditional, to pay the principal of, premium, if any, and interest, if any, on each obligation at the times, places, and rates, and in the coin or currency, identified on
the records of the Issuer. 
  
 At the request of the registered owner, the Issuer
shall promptly issue and deliver one or more separate note certificates evidencing each obligation evidenced by this Master Note. As of the date any such note certificate or certificates are issued, the obligations which are evidenced thereby shall
no longer be evidenced by this Master Note. 
  
 ====================================================================================================== 
  
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers unto 
  
                                       
                                        
                                        
                                        
                                        
                                        
                    
 (Name, Address, and
Taxpayer Identification Number of Assignee) 
  
 the Master Note and all rights
thereunder, hereby irrevocably constituting and appointing
                                 attorney to transfer said Master Note on the
books of the Issuer with full power of substitution in the premises. 
  

					
	 Dated:
	 	 	 	 
	 	 	 	 	(Signature)
	 Signature(s) Guaranteed:
	 	 	 	NOTICE: The signature on this assignment must correspond with the name as written upon the face of this Master Note, in every particular, without alteration or enlargement or any change
whatsoever.

  
 Unless this certificate is presented
by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”), to the Issuer or its Agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede
& Co. or in such other name as is requested by an authorized representative of DTC (and any payment is made to Cede & Co. or to such other entity as is requested by an authorized representative of DTC)., ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein. 
  

	**	Senior, which are designated JPMorgan Chase Senior Notes, Series D, due Nine Months or More from the Date of Issue.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]